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Abstract 
Heterochromatin Protein 1 (HEP1) is a highly conserved, chromatin re-
modelling protein involved in activation and repression of secondary metabolite 
producing gene clusters. In-house genome sequencing of the plant growth 
promoting and biocontrol fungus Trichoderma hamatum GD12 has shown that 
~40 % of the genome is unique to GD12 compared to its closest relatives, 
suggesting enormous genetic potential to encode novel bioactive compounds 
with antimicrobial and PGP activities. It is apparent that under axenic 
conditions, a substantial proportion of the bioactive potential of the fungus is not 
expressed. We therefore hypothesised that loss of HEP1 would lead to 
activation of cryptic gene clusters responsible for the production of novel 
bioactive secondary metabolites. Identification of compounds with antimicrobial 
activities might benefit a growing population faced with numerous multidrug 
resistant microorganisms. HEP1 was inactivated in T. hamatum GD12 using the 
split-marker method of homologous recombination and ∆ThhepA::hph strains 
were confirmed via DIG-labelled Southern blot analysis. Phenotypic analysis 
revealed significantly reduced hyphal growth of hepA mutants compared to 
GD12. Confrontation assays of GD12 and three independent ∆ThhepA::hph 
strains against fungal pathogens revealed a change in the biocontrol activities, 
with a zone of inhibition surrounding mutant strains suggesting the secretion of 
inhibitory bioactive compound(s). Liquid chromatography-mass spectrometry 
was used to determine the secretome profiles of hepA mutants. Analysis of the 
data revealed a number of key features which are differentially expressed in 
hepA mutants. One such feature of particular interest is Brefeldin A, which 
functions as an antimicrobial agent. This project would benefit from 
characterisation of key features to determine their antimicrobial potentials.
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1. Introduction 
Trichoderma species are ubiquitous soil saprotrophs that are renowned for their 
prolific secretion of secondary metabolites (SMs)1, low-molecular-mass 
compounds which, unlike primary metabolites, are not essential for the growth 
and development of the organism producing them. Plants and microorganisms 
produce SMs as a survival mechanism and humans have been able to utilise 
these compounds for medical use due to their pharmaceutical and toxicological 
properties2. With the global population expected to exceed 9 billion by 20503 
and antibiotic resistance becoming more prominent4, the ability to identify 
microorganisms that produce novel compounds with active biocontrol 
capabilities on a large scale becomes increasingly important. 
Substantial portions of microbial genomes are dedicated to the production of 
SMs5,6, yet under standard laboratory conditions it is clear that the 
overwhelming majority of this biosynthetic potential is not expressed5–7. 
Secondary metabolites are derived from complex gene clusters8 which are often 
located within the subtelomeric region of chromosomes9,10. This project set out 
to activate such a cryptic gene cluster in the beneficial rhizosphere fungus T. 
hamatum GD12 in an attempt to identify novel compounds for use as 
antimicrobial agents. 
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1.1 Trichoderma hamatum GD12 is unique 
Trichoderma spp., are members of the largest group of fungi, the Ascomycota. 
Some strains have been shown to elicit plant-growth-promotion (PGP) through 
secretion of PGP compounds11,12, whereas others display biocontrol against a 
broad range of pathogens through a variety of mechanisms. For example, 
activation of induced systemic resistance (ISR) in plants by Trichoderma spp., 
has been shown to elicit biocontrol against the bacterial pathogen 
Pseudomonas syringae13 and the fungal pathogen Botrytis cinerea14. 
Competition for nutrients is the mode of action used by many Trichoderma spp. 
such as biocontrol of Fusarium wilt disease of tomatoes by Trichoderma 
asperellum15. Many Trichoderma spp. produce cell wall-degrading enzymes 
such as chitinase that medicate biocontrol during physical interactions with 
pathogens, such as during antagonism of the devastating white mould fungus, 
Sclerotinia sclerotiorum16. Trichoderma spp. also produce secondary 
metabolites which have been shown to elicit PGP activity17. 
The T. hamatum GD12 genome was sequenced in-house and a draft genome 
assembled from 12 million pairs of Illumina GA2 paired-end 73-bp reads using 
Velvet 1.1.04. BLASTP analysis of the 38.2 Mb whole genome shotgun 
sequence,  deposited at DDBJ/EMBL/GenBank under the accession 
ANCB0000000018, against four other Trichoderma spp. revealed a conserved 
‘core’ proteome of 3620 proteins. The close relative T. atroviride shares an 
additional 2096 predicted proteins with GD12 supporting the hypothesis that 
divergence of species occurred very recently on an evolutionary scale. A large 
portion of the predicted proteome is unique to T. hamatum GD12, comprising 
4658 predicted proteins, some with potential bioactive capabilities (Figure 1A). 
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Prediction of the T. hamatum GD12 secretome was carried out via SignalP 4.019 
analysis against four other Trichoderma species revealing a secretome of 327 
core predicted secretion proteins found unanimously across all five of the 
Trichoderma spp. analysed (Figure 1B). Interestingly, the number of predicted 
secretome proteins unique to T. hamatum is greater than that of the predicted 
‘core’ secretome, at 370 predicted proteins. Evidence of recent species 
divergence between T. hamatum and T. atroviride is present again within the 
predicted secretome, with 164 secretion proteins predicted to be shared 
between the two fungi, the highest of all Trichoderma pairwise comparisons. 
From these findings we hypothesised that, based on the large number of 
predicted and secreted proteins which are unique to GD12, it is highly probably 
that there are cryptic gene clusters present within T. hamatum GD12 that have 
potential to encode an abundance of novel bioactive secondary metabolites.
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Figure 1 | Venn diagrams showing the conservation of the predicted 
proteome and secretome of Trichoderma hamatum GD12 compared with 
other Trichoderma spp. [Taken from Studholme et al. 201318] The GD12 
genome was sequenced in-house using Illumina GA2 paired-end 73-bp reads 
using Velvet 1.1.04. BLASTP and SignalP were used to analyse the 
conservation of the predicted proteome and secretome of GD12 compared with 
4 other Trichoderma spp. (A) T. hamatum GD12 shares a core proteome of 
3620 predicted proteins with T. atroviride, T. virens, T. reesei and T. harzianum. 
T. hamatum GD12 also has 4658 unique predicted proteins and shares close 
homogly with T. atroviride. (B) A predicted secretome analysis from SignalP 
identified 327 core secreted proteins common to all Trichoderma spp. and 370 
which were unique to T. hamatum GD12 alone. 
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1.2 Synthesis of secondary metabolites through biosynthetic pathways 
Secondary metabolites are derived from biosynthetic genes typically found in 
clusters20 within the sub-telomeric region of chromosomes, although there are 
exceptions21. Biosynthetic genes encode large multidomain, multimodular 
enzymes (Figure 3) which synthesize polyketides (PKS), such as the mycotoxin 
aflatoxin B1, or non-ribosomal peptides (NRPS) such as the common antibiotic 
penicillin G (Figure 2). Although the majority of SMs are derived from one of 
these two pathways, there are exceptions. Some SMs, such as the toxin 
coronatine, produced by the bacterial plant pathogen Pseudomonas syringae 
during host infection, are derived from a hybrid PKS-NRPS22,23. The SM 
ergotamine is derived from NRPS but requires a tryptophan 
dimethylallytransferase for synthesis24 and the plant hormones gibberellins, 
which are also produced by a range of fungi, are derived independently of PKS 
and NRPS but require a terpene cyclase for synthesis25. 
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Figure 2 | Examples of fungal secondary metabolites. [Taken from 
Brakhage, 201329] Fungal secondary metabolites are produced through 
multimodular, multidomain biosynthetic pathways. Penicillin G, cyclosporine 
A and gliotoxin are all derivatives of non-ribosomal peptide synthetases 
(NRPS - represented in light grey). Aflatoxin B1 and lovastatin are derived 
from polyketide synthases (PKS – represented in red). NRPS and PKS 
constitute the majority of secondary metabolites. Others include aspyridone 
A which is derived from the hybrid pathway PKS-NRPS (represented in 
blue), ergotamine which is derived from the NRPS pathway but requires a 
tryptophan dimethylallyltransferase for synthesis (shown in dark grey), and 
finally gibberellin A3, plant hormones which are also produced by some 
fungi and derived independently from both PKS and NRPS pathways but 
require a terpene cyclase for synthesis (shown in green). 
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Synthesis of SMs begins with malonyl and amino acid building blocks for PKS 
and NRPS respectively, or derivatives thereof26–28, which are passed along a 
series of modules, each of which is responsible for one discrete elongation step 
(Figure 3). For NRPS synthesis, three minimal domains are required; an 
adenylation domain (A: activation of amino acid building block), a peptidyl 
carrier protein (PCP, also known as thiolation domain: binds cofactor 4’PP to 
which an activated amino acid covalently attaches), and a condensation 
domain (C: catalyses peptide bond formation). Additional extensions and 
modifications may include a methyltransferase (MT: addition of a methyl group), 
a β-ketoacyl reductase (KR: reduction of a ketoacyl group), and/or an 
epimerization (E: changing of one asymmetric centre in a compound). Similarly 
to NRPS, PKS also requires a minimum of three domains; an acyltransferase 
domain (AT: extender unit selection and transfer), an acyl-carrier protein 
(ACP: extender unit loading), and a ketoacyl synthase domain (KS: 
decarboxylative condensation of extender unit with an acyl thioester). The 
resulting product is a β-ketothioester which may undergo additional elongation 
and modification via a β-ketoacyl reductase domain, a dehydratase domain 
(DH: loss of H2O), an enoyl reductase domain (ER: reduces a β-double bond to 
a single bond), and/or a methyltransferase domain.  
17 
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Figure 3 | Synthesis of secondary metabolites through gene clusters. [Taken from 
Brakhage, 201329] Secondary metabolites are derived from biosynthetic pathways 
which contain multimodular, multidomain enzymes, each of which is responsible for one 
discrete elongation step.  Polyketide synthase domains (left) begin with a malonyl 
starter unit and require a minimum of three domains for synthesis; a ketoacyl synthase 
(KS) domain, an acyltransferase (AT) domain and an acyl-carrier protein (ACP) domain. 
Optional elongation steps may include; an enoyl reductase (ER) domain, a dehydratase 
(DH) domain and a β-ketoacyl reductase (KR) domain. These enzymes are flanked by a 
starter ACP transacylase (SAT) domain and a termination domain (TE). Non-ribosomal 
peptide synthetases begin with an amino acid starter unit and also contain a minimum 
of three domains for synthesis; a condensation (C) domains, an adenylation (A) domain 
and a peptidyl carrier protein (PCP) domain. Additional elongation steps may include; a 
methyltransferase (MT) domain, a β-ketoacyl reductase (KR) domain and an 
epimerization (E) domain. These enzymes are flanked by a PCP domain, which binds 
the cofactor 4’-phosphopantetheine (4’PP), to which the activated amino acid starter 
unit is covalently attached and a termination domain. 
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1.3 Fungal secondary metabolism 
Chromatin exists in two forms: euchromatin, the ‘on’ state when genes are 
actively being transcribed, and the condensed state - heterochromatin, when 
the gene cluster is repressed. It is not yet fully understood how this pathway 
functions, but a proposed mechanism is illustrated in Figure 4 30. 
Methylation residues on lysine 4 of histone 3 (H3K4-CH3) and acetylation 
residues are commonly associated with active gene transcription in 
euchromatin. Unknown silencing factors are thought to initiate histone 
deacetylase (HDAC) to remove acetylation residues from histones31, and the 
addition of a methyl group to histone 3 lysine 9 is achieved via H3K9 
methyltransferase (ClrD), subsequently creating the binding site for 
Heterochromatin Protein 1 (HEP1)32. The addition of HEP1 to the complex 
causes chromatin to condense into heterochromatin, effectively silencing the 
gene cluster. Gene clusters remain silent until they are reactivated when 
unknown environmental stimuli are translated into signal cascades which are 
able to act both dependently and independently through the LaeA containing 
Velvet complex33. The removal of methylation from H3K9 by the COMPASS 
complex34 and subsequent acetylation via histone acetyltransferase (HAT)35 
initiates gene transcription through RNA polymerase II (Pol II)36.  
20 
 
       
 
Figure 4 | A proposed model for chromatin regulation of secondary metabolite gene clusters. [Taken from Palmer et 
al. 201030 (A) and Palmer et al 200837 (B)]. It is thought that unknown silencing factors initiate histone deacetylase to remove 
acetyl groups from chromatin, which are commonly associated with active gene transcription, euchromatin. This is turn allows 
methylation of histone 3 lysine 9 (H3K9) by ClrD, creating the binding site for heterochromatin protein 1, HEP1. The addition 
of HEP1 to the complex causes to chromatin to condense into the silent state of heterochromatin, repressing the gene 
cluster. Initiation of active transcription occurs when environmental stimuli are transcribed into signal cascades which act both 
dependently and independently of the LaeA containing Velvet Complex. Histone acetyltransferase (HAT) allows methylation 
of H3K4 and the COMPASS complex allows active gene transcription through RNA polymerase II (Pol II). 
A B 
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1.4 Heterochromatin Protein 1 (HEP1) 
Heterochromatin protein 1 (HEP1) is a highly conserved eukaryotic protein first 
identified in Drosophila melanogaster as a dominant suppressor of position-
effect variegation38 – translocation of euchromatic genes to the vicinity of 
pericentric heterochromatin where they acquire a variegated pattern of 
expression. Since this initial discovery, orthologs have been found in a broad 
range of eukaryotic organisms, with many carrying multiple copies (Figure 5)39. 
Genomes of the fission yeast Schizosaccharomyces pombe and the red bread 
mould Neurospora crassa each contain one HP1 homolog, whereas the soil-
living amoeba Dictyostelium discoideum has two. Some animal species are 
known to have up to five HP1 orthologs within their genomes with 50% amino-
acid sequence identity between mammalian HP1 and the homolog found within 
Drosophila40. 
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Figure 5 | Phylogenetic tree showing Heterochromatin Protein 1 
homology. [Taken from Lomberk et al 200639]. Heterochromatin protein 1 is a 
highly conserved eukaryotic protein with roles in activation and silencing of 
gene clusters by chromatin remodelling. Species shown include the fission 
yeast Schizosaccharomyces pombe (Sp), the red bread mould Neurospora 
crassa (Nc), the soil nematode Caenorhabditis elegans (Ce), the common fruit 
fly Drosophila melanogaster (Dm) and its close relative Drosophila virilise (Dv), 
the African claw-toed frog Xenopus laevis (Xl), Gallus gallus more commonly 
known as the red junglefowl (Gg), the house mouse Mus musculus (Mm), the 
human species Homo sapiens (Hs) and the soil-living amoeba Dictyostelium 
discoideum (Dd). 
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Structurally, HEP1 consists of two highly conserved domains, the chromo 
domain and the chromo-shadow domain, which are connected via a variable 
linker region (Figure 6)39. The amino terminal half of the protein, the chromo 
domain, is responsible for gene-silencing by altering the structure of chromatin 
to produce heterochromatin. This is achieved by three conserved aromatic 
residues, identified as tyrosine-24 (Tyr(Y)), tryptophan-45 (Trp(W)) and Tyr-48 
within Drosophila, which form a three walled aromatic cage creating a 
hydrophobic pocket which allows the chromo domain to dock with methylation 
residues on di- and trimethylated H3K941,42. The carboxy-terminal half of the 
protein, the chromo-shadow domain, is responsible for homo- and 
heterodimerization and interaction with other chromatin associated 
molecules32,43. The linker or hinge-region which separates the chromo domain 
from the chromo-shadow domain contains the least conserved amino acid 
sequence between HEP1 orthologs, and is thought to be flexible and exposed 
to the surface44. 
 
 
Figure 6 | The conserved linear structure of Heterochromatin Protein 1. 
[Taken from Lomberk et al 200639]. The highly conserved structure of 
heterochromatin protein 1 consists of an amino (N)-terminal chromo domain 
which binds to chromatin altering its structure, and the carboxy (C)-terminal 
chromo-shadow domain which is responsible for binding to other chromatin 
associated molecules. These two highly conserved domains are connected by a 
more variable linker region. 
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1.5 Project aims 
Trichoderma spp. are renowned for being prolific producers of bioactive 
secondary metabolites which have been utilised in a range of applications, such 
as medicine and chemical manufacturing. Under axenic laboratory conditions it 
appears that an overwhelming proportion of the bioactive potential is not 
expressed. Activation of such cryptic gene clusters may reveal novel secondary 
metabolites with bioactive properties. Analysis of the genomic gene clusters 
involved in secondary metabolite production suggest a ‘mosaic’-type pathway, 
where regulatory proteins, such as HEP1, play a key role in chromatin re-
modelling. 
The objective of this project was to identify a HEP1 homolog within T. hamatum 
GD12 and to investigate the antimicrobial activities of HEP1-deficient mutants. 
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2. Materials and methods 
2.1 Growth and maintenance of strains 
Long term growth and maintenance of all strains and pathogens used 
throughout this project (Table 1) was carried out on malt extract agar (MEA: 2 % 
[w/v] malt extract, 2 % [w/v] agar) and grown for experimentation on potato 
dextrose agar (PDA: 2.4% [w/v] potato dextrose, 2 % [w/v] agar) unless stated 
otherwise. During active growth, fungal and yeast strains were incubated at 26 
°C with a 24 h light cycle consisting of 16 h light and 8 h dark. 
 
Table 1 | Strains and isolates used within this project. 
KD: Katherine Denby, Life Sciences, University of Warwick. SB: Steve Bates, 
School of Biosciences, University of Exeter. CBS: Centraalbureau voor 
Schimmelcultures, Utrecht, The Netherlands. JW: Jon West, Rothamsted 
Research, Harpenden, Hertfordshire. 
Organism Isolate number Source 
Botrytis cinerea R2 KD 
Candida albicans SC5314 SB 
Candidia tropicalis 1920 CBS 
Filobasidiella (Cryptococcus) neoformans 10490 CBS 
Fusarium oxysporum f.sp. lycopersici 167.3 CBS 
Geotrichum candidum 115.23 CBS 
Pythium ultimum var. ultimum 656.68 CBS 
Rhizoctonia solani   
Sclerotinia minor   
Sclerotinia sclerotiorum BFS JW 
Sclerotinia sclerotiorum GFR1 JW 
Sclerotinia sclerotiorum GFR11 JW 
Sclerotinia sclerotiorum M448 JW 
Trichosporon asahii 892 CBS 
Trichosporon asteroides 6183 CBS 
Trichosporon inkin 7630 CBS 
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2.2 Fungal genomic DNA extraction 
T.hamatum GD12 mycelium was obtained by inoculating 100 mL potato 
dextrose broth (PDB: 2.4% [w/v] potato dextrose) with 4 x 5 mm diameter plugs 
of actively growing T. hamatum GD12 mycelia, taken from the leading edge of 
cultures 2 days post inoculation (d.p.i.). Cultures were incubated at 26 °C for 72 
h at 125 rotations per minute (rpm) before filtering through sterile miracloth, 
washing with sterile deionised water and flash-freezing in liquid nitrogen. 
Mycelia was ground to a fine powder using a sterile pestle and mortar, which 
had been chilled using liquid nitrogen. The powder was transferred to a 2 mL 
microfuge tube containing 1 mL SDS-buffer (1 % [w/v] SDS, 0.025 M EDTA (pH 
8.0), 0.25 M NaCl, 0.2 M Tris-HCl (pH 8.0)) and incubated at 65 °C for 30 min. 
Cellular debris was removed by centrifugation at 14,000 rpm for 10 min at room 
temperature and the supernatant decanted into a fresh sterile 1.5 mL microfuge 
tube. For nucleic acid purification, 800 µL phenol (pH 8.0) was added to each 
tube, the tubes vortexed and residual debris removed by centrifugation as 
previously described. To further purify the aqueous phase containing nucleic 
acid, two further extractions were carried out with 800 µL phenol:chloroform 
[1:1] and CIA, respectively. Nucleic acid was precipitated from the supernatant 
by adding 0.6 vol. of ice-cold isopropanol, vortexing for an even distribution and 
incubating at -20 °C for 30 min. Nucleic acids were harvested by centrifugation 
at 14,000 rpm for 10 min at 4°C, the supernatant removed and the pellet 
washed with 500 µL ice-cold 70 % [v/v] ethanol. Samples were pelleted for 5 
min at 14,000 rpm, room temperature, residual ethanol removed with a pipette 
and the pellet dried before re-suspension in 30 µL sterile milliQ water. RNA was 
removed with RNase and the concentration of DNA determined by Nanodrop 
28 
 
spectrophotometer (Thermo Scientific) and gel electrophoresis.
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2.3 Creation of ∆ThhepA::hph mutants 
2.3.1 Creation of hepA knockout cassette 
The split marker method of homologous recombination was used to replace the 
hepA gene of T. hamatum with the hygromycin resistance conferring hph gene 
from Escherichia coli under a Neurospora crassa promoter. The split marker 
cassettes were created by a series of PCR reactions outlined in Appendices 6.1 
and 6.2. Each master mix consisted of 9.5 µL GoTaq® Green Master Mix 
(Promega), 1 µL forward primer (10 pM), 1 µL reverse primer (10 pM), 50 ng 
template DNA and sterile milliQ water to a final volume of 25 µL.  PCR reactions 
were analysed by gel electrophoresis on an agrose gel (0.8% [w/v] in TAE) 
containing 0.5 µg mL ethidium bromide to visualise DNA. PCR products were 
run alongside a GeneRuler 1kB ladder (Fermentas). QIAquick Gel Extraction Kit 
(Qiagen) was used to purify PCR products from agarose gels according to the 
manufacturer’s protocol and the final concentration of purified products were 
determined by gel electrophoresis (Figure 9). 
 
2.3.2 Protoplast transformation of Trichoderma hamatum GD12 
Conidia of T.hamatum GD12 were harvested from V8 agar plates (V8: 20 % 
[v/v] V8 juice, 1 % [w/v] D-glucose), 2 % [w/v] agar, to volume with milliQ water) 
7 d.p.i by agitation in sterile milliQ water. Twenty mL PDB was inoculated with 
106 c.f.u mL-1 and incubated at 26 °C for 48 h, static. Mycelia were harvested 
via filtration through sterile miracloth and residual PDB removed by washing 
with sterile milliQ H2O. Fungal biomass was weighed to 0.6g and incubated in 
2.4 mL filter sterilised (0.22 µm) enzyme solution containing 1.2 mg chitinase 
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(Sigma), 1 mg lyticase (Sigma) and 44 mg cellulose (Sigma) in mannitol 
osmoticum ((50 mM CaCl2, 0.5 M Mannitol) adjusted to pH 5.5 with KOH)) at 
room temperature and shaken at 225 rpm. After 25 min, the protoplast 
concentration was determined by counting under a haemocytometer (107 
protoplasts mL-1 desired), with the incubation period preceding no longer than 
45 min. Fungal debris was removed from the protoplast mixture by filtering 
through sterile miracloth and the protoplasts harvested by centrifugation at 
5,500 rpm for 5 min at 4 °C. The pellet was gently re-suspended in 300 µL filter 
sterilised mannitol osmoticum. The centrifugation and re-suspension step was 
repeated two times to remove any residual enzyme mixture, with the protoplasts 
finally being re-suspended in 240 µL filter sterilised mannitol osmoticum. Five 
µg of each hepA LF + HY and hepA RF + YG purified PCR products (no more 
than 40 µL total) were added to the protoplast suspension then the mixture 
incubated on ice for 20 min before 130 µL of PEG solution (40 % [w/v] PEG 
4000 in mannitol osmoticum) was added and mixed by inversion. A further 130 
µL of PEG solution was added to the mixture, again mixed by inversion, and 
incubated at room temperature for 30 min. The protoplast suspension was 
gently mixed with 150 mL PDA + sucrose agar (PDA with 0.8 M sucrose) at 42 
°C which was poured into five x 9 cm petri dishes to solidify. Plates were 
incubated in the dark at 26 °C for 24 h before a PDA + 600 µg mL-1 hygromycin 
overlay was applied as a selection layer to each plate. Plates were returned to 
the dark and checked daily for putative transformants which were isolated from 
the surface of the overlay layer and sub-cultured on to PDA + 600 µg ml-1 
hygromycin. To ensure stability of the hph gene and also to ensure that each 
putative transformant was selected from an individually transformed protoplast, 
single spore isolation was carried out by growing each strain on V8 agar and 
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harvesting conidia 7 d.p.i. Conidia were diluted to 102 c.f.u-1 and grown on PDA 
+ 600 µg-1 at 26 °C until individual transformants emerged. These were selected 
and sub-cultured on to V8 agar and the single spore isolation process was 
repeated once more. 
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2.4 DIG-Southern blot analysis 
2.4.1 Creation of DIG-labelled left flank probe 
To create the DIG-labelled probe, PCR of the left flanking region was carried 
out using 40 µL buffer HF 5X (Promega), 20 µL DIG-labelled nucleotides 
(Roche), 4 µL hepA_LF_LP, 4 µL hepA_LF_RP, 2 µL Phusion® Taq DNA 
Polymerase (New England BioLabs, NEB), 50 ng of previously purified LF 
product and sterile milliQ water to a final volume of 200 µL. The master mix was 
divided in to four x 50 µL aliquots and the PCR cycle run with an annealing 
temperature of 55 °C and a 30 s extension time. PCR products were analysed 
on a 0.8 % TAE agarose gel and the product purified as described above with 
the final product being eluted in 20 µL milliQ water before being added to 20 mL 
pre-warmed (to eliminate precipitation) Southern Hybridization buffer (NaPO4 - 
pH 7 (0.5 M), 7 % SDS). 
 
2.4.2 Confirmation of ∆ThhepA::hph strains 
Genomic DNA was extracted from the putative transformants as described 
previously, and 20 µg of each putative transformant, plus a GD12 control, were 
digested using 3 µL StuI restriction enzyme (NEB), 5 µL buffer 10X, 0.5 µL BSA 
and sterile milliQ water to a final volume of 50 µL. Restriction digests were 
incubated overnight at 37 °C and the following day were run on a 0.8 % TAE 
agarose gel. The gel was placed well-side down in a trough and depuration was 
carried out by shaking for 15 min in 50 mL 0.25 M HCl. The HCl was then 
replaced with 50 mL 0.4 M NaOH for a further 15 min to allow neutralisation. To 
transfer the digested DNA to a membrane, a blot was performed by filling a 
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large trough with 0.4 M NaOH and placing a piece of Perspex® plastic over the 
trough as a bridge. A large strip of Whatman® paper soaked in 0.4 M NaOH 
was draped over the bridge with each end in the 0.4 M NaOH solution to act as 
a wick. The gel was placed in the centre of the Whatman® paper wick with wells 
facing up. A piece of Amersham Hybond-NX membrane (GE Healthcare) cut to 
the size of the gel was placed on top of the gel using forceps (the membrane 
was not moved once touching the gel), followed my two pieces of Whatman 
paper cut to the same size as the gel and finally a stack of paper towels. 
Another piece of Perspex was placed on top of the paper towels and pressure 
applied to the stack from the top. SeranTM wrap was placed down each side of 
the bridge to enhance the capillary effect and prevent precipitation of the 0.4 M 
solution and the blot was left overnight. The paper towels and Whatman® paper 
squares were discarded and the membrane transferred to a hybridisation tube 
along with 50 mL Southern Hybridization Buffer and incubated at 62 °C for 30 
min. Meanwhile, the probe was boiled in a 100 °C water bath for 10 min. The 
Southern Hybridization buffer in the hybridization tube was discarded and 
replaced with the boiled probe and the membrane was then left to incubate at 
62°C overnight. The probe was removed and the membrane washed twice for 
15 min at 62 °C with 20 mL Southern Wash Buffer (NaPO4 – pH 7 (0.1 M), 1 % 
[w/v] SDS) in the hybridization tube. The membrane was transferred to a trough 
and washed for 5 min in 20 mL DIG-wash buffer (0.3 % Tween 20, DIG Buffer 1 
(maleic acid (0.1 M), NaCl (0.15 M) adjusted to pH 7 with NaOH)) at room 
temperature with agitation. The DIG-wash buffer was then removed and 
replaced with 25 mL DIG Buffer 2 (1 % [w/v] semi-skimmed milk powder in DIG 
Buffer 1) and the membrane incubated for 30 min with agitation. After 30 min, 
the Blocking solution was replaced with 20 mL Antibody solution (anti-DIG AB 
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(Roche) as a 1:10000 dilution) in DIG Buffer 2) and incubated for a further 30 
min at room temperature with agitation. The membrane was then washed twice 
with 20 mL DIG-wash buffer for 15 minutes at room temperature with agitation, 
and then equilibrated for 5 min in 20 mL DIG-buffer 3 (Tris-HCl (0.1 M), NaCl 
(0.1 M) MgCl2 (50 mM); adjusted to pH 9.5 with HCl). The membrane was 
removed from the trough using forceps and placed in a plastic envelope with 1 
mL CDP-Star (Roche) solution pipette on the surface of the membrane. The 
plastic envelope was closed and bubbles removed, to ensure the CDP-star 
solution covered the entire surface of the membrane, and incubated at room 
temperature for 5 min. CDP-star was then thoroughly drained from the 
membrane on to paper towel and the membrane sealed in a fresh plastic 
envelope, placed into a film cassette and incubated for 15 min at 37 °C. In a 
dark room, an X-ray film (Fujifilm) was exposed to the membrane and the 
cassette closed and incubated at room temperature for 1 min before the film 
was developed. 
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2.5 Phenotypic Analysis 
2.5.1 Growth curves 
T. hamatum strains were grown on PDA in 15 cm square petri dishes and 
incubated at 26 °C in both light and dark conditions. Plates were scanned daily 
over a 14 day period using an Epson Perfection V750 Pro scanner, and growth 
of mycelia recorded as mm2 using imageJ. 
 
2.5.2 Confrontation assays 
To determine the biocontrol effects loss of HEP1 has on various pathogens in 
comparison to the wild-type strain, 5 mm plugs of mycelia from T. hamatum 
strains and fungal pathogens (Table 1) were taken from the leading edge of 
cultures 2 d.p.i and placed at opposite sides of 9 cm petri dishes containing 
PDA. Yeast pathogens were sub-cultured on to PDA plates containing T. 
hamatum strains 3 d.p.i using a sterile inoculation loop. Plates were incubated 
at 26 °C and interactions recorded 5 d.p.i of T. hamatum.  
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2.6 Genome mining for secondary metabolite gene clusters 
Sequencing of the T. hamatum GD12 genome was previously carried out in-
house using Illumina sequencing technology. The genome was subsequently 
analysed for secondary metabolite gene clusters using the genome mining 
antiSMASH 2.0 platform45. A BLASTP analysis was performed on the output 
against the Aspergillus nidulans FGSC_A4 proteome (NCBI Taxonomy ID: 
227321). The protein output was then aligned to the A.nidulans FGSC_A4 
genome using the Integrative Genomics Viewer (IGV)46 to determine the 
chromosomal location of secondary metabolite gene clusters. 
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2.7 LC-MS analysis 
2.7.1 Sample preparation 
Cultures of S. sclerotiorum M448 only, ∆ThhepA::hph2 only, T. hamatum GD12 
confronted with S. sclerotiorum M448 and ∆ThhepA::hph2 confronted with S. 
sclerotiorum M448 were grown on PDA plates. After 48 h, the uncolonised 
media between the confrontation cultures, or the media surrounding the leading 
edge of lone cultures was extracted, along with non-inoculated PDA, made up 
to 50 mL with sterile milliQ water and incubated at 4 °C for 72 h. Extracts were 
then filtered through sterile miracloth and the supernatants collected, flash-
frozen in liquid nitrogen and freeze-dried. Samples were re-suspended to 10 % 
of the original volumes (in this case 500 µL) in 10 % Methanol + 7.2 µg ml-1 
umbeliferone as an internal standard, centrifuged for 10 min at 16,000 rpm, 4 
°C, and filtered through a 0.2 µm filter on ice. 
2.7.2 Analysis of secondary metabolite samples 
Samples were run twice on LC-MS using a Polaris reversed phase C18 column 
– once in positive and once in negative ion modes, on an Agilent Quantitative-
Time-Of-Flight (QTOF) mass spectrometer using electrospray ionisation. The 
LC-MS was run in full scan mode with tandem MS capabilities. Features were 
subsequently extracted using the Molecular Feature Extraction algorithm in 
Agilent’s MassHunter software (Agilent Technologies, Germany) and the 
deconvoluted data aligned using an in-house Kernel Feature Alignment 
algorithm. Only features present in two out of three of the replicates were 
considered ‘true’. 
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3. Results 
3.1 Bioinformatics analysis of the Trichoderma hamatum GD12 genome 
It has been hypothesised that regulation of gene clusters is dependent on 
chromosomal location30, and gene clusters that regulate secondary metabolites 
are typically found within the subtelomeric region9,30,47. The antiSMASH output 
of the T. hamatum GD12 genome (Appendices 6.4) was subjected to BLASTP 
analysis against the extensively annotated genome of the closely related fungus 
A. nidulans FGSC_A4, and the protein sequence of the latter aligned against 
the genome in IGV. Figure 7 shows the distribution of SM gene clusters within 
the genome, with the height of the peak directly correlating to the number of 
secondary metabolite genes located within that region. It is clear that the 
majority of SM genes are located towards the ends of chromosomes, 
particularly chromosomes two and seven. As to whether or not these genes lay 
within the subtelomeric region would require further investigation into what 
depicts such a region. 
Figure 7 | Alignment of secondary metabolite gene clusters against the 
Aspergillus nidulans genome. The genome of T. hamatum GD12 was 
interrogated for secondary metabolite gene clusters using the genome mining 
software antiSMASH. BLASTP analysis was performed with the resulting 
protein output against the A. nidulans FGSC_A4 genome. The protein 
sequences from A. nidulans were aligned against its genome to determine the 
location of SM gene clusters. The height of each peak is relative to the number 
of genes found within that region. It is apparent that the majority of SM genes 
are located towards the end of chromosomes, particularly chromosomes two 
and seven. 
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3.2 Heterochromatin Protein 1 is highly conserved 
HEP1 is a highly conserved protein with orthologs found in a broad range of 
eukaryotic organisms. Functionally, HEP1 is involved in chromatin re-modelling 
for activation and silencing of gene clusters. A HEP1 homolog was identified 
within the T. hamatum GD12 genome (Figure 8A). The coding sequence (CDS) 
for the HEP1 protein consists of 5 exons which are interrupted by 4 introns. 
HEP1 is defined by two highly conserved domains, an amino-terminal chromo 
domain and a carboxy-terminal chromo-shadow domain which are separated by 
a more variable linker region, thought to act as a hinge. The amino acid 
sequence of the GD12 homolog was aligned against an amino acid sequence 
from the closely related T. atroviride along with chromo domain and chromo-
shadow domain sequences from N. crassa, H. sapiens and D. melanogaster 
using Clustal omega (Figure 8B). High levels of conservation are seen within 
the chromo domain (dark blue box) and chromo-shadow domain (light blue 
box). It was demonstrated in Drosophila that three aromatic residues (Tyr-24, 
Trp-45 and Tyr-48) are required to form a ‘cage-like’ structure creating a 
hydrophobic pocket to which methylation residues on H3K9 can bind48. The 
latter two of these aromatic residues were identified in GD12 (highlighted in 
red), however, the former appears to have either been misaligned (highlighted 
in aqua) or a possible SNP has taken place (indicated in green). 
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Figure 8 | Schematic diagram showing the locations of the chromo and 
chromo-shadow domains within the hepA coding sequence. HEP1 is 
comprised of two highly conserved domains, the amino-terminal 
chromodomain, and the carboxy-terminal chromo-shadow domain, which are 
separated by a more variable linker region. A The coding sequence (CDS) is 
comprised of 5 exons (grey boxes), which are interrupted by 4 introns (black 
lines). The chromo domain is indicated by a dark blue box, whereas the 
chromo-shadow domain is indicated by a light blue box. B A protein alignment 
of the HEP1 protein sequence show high levels of conservation within T. 
hamatum GD12 (Th) compared with T. atroviride (Ta) and the chromo and 
chromo-shadow domain protein sequences of Neurospora crassa (Nc), Homo 
sapiens (Hs) and Drosophila melanogaster (Dm). Asterisks represent identical 
amino acids, and colons and periods represent strong and weak conservation, 
respectively. The three amino acids required to create the aromatic cage which 
binds methylation residues on lysine 9 of histone 3 are indicated in red, with a 
potential single nucleotide polymorphism (SNP) resulting in a different amino 
acid represented in green. Possible misalignment is represented in turquoise. 
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3.3 Confirmation of ∆ThhepA::hph strains 
Loss of HEP1 was achieved by using the split marker method of homologous 
recombination to replace the hepA ORF with the hph gene conferring 
hygromycin resistance (Figure 9). 
 
Figure 9 | Schematic diagram showing the split-marker method for 
creating the knockout cassette used for generating ∆ThhepA::hph strains. 
PCR amplicons were separated on 1.2 % agarose gels and were flanked by 10 
µL and 5 µL of Fermentas 1 Kb GeneRuler ladder, respectively, unless stated 
otherwise. For quantification purposes, 10 µL, 5 µL and 2 µL of gel purified PCR 
products were loaded on to each gel respectively: a) left flanking region of hepA 
gene (1016 bp); b) right flanking region of hepA gene (940 bp); c) amplification 
of the former part of the hph gene (HY – 1200 bp); d) amplification of latter part 
of the hph gene (YG – 800 bp); e) second round Phusion® PCR product of LF + 
HY (2210 bp); f) second round Phusion® PCR product of RF + YG (1740 bp). 
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Confirmation of ∆ThhepA::hph strains was carried out by digestion of genomic 
DNA using the restriction enzyme StuI (5’-AGG^CCT-3’) (Appendices 6.3) and 
subsequent Southern blot analysis using a digoxigenin – dUTP (DIG) labelled 
probe of the left flanking region, ~1 Kb upstream, of the hepA open reading 
frame. A band size of 3201 bp confers a wild-type strain, whereas a band size 
of 6811 bp confers a hepA knockout mutant strain. The resulting Southern blot 
(Figure 10) confirms all putative hepA deletion mutants when compared to the 
wild-type strain GD12. Due to lack of another selectable marker, creation of a 
complementation strain is currently not possible, therefore, three independent 
hepA deletion mutants were selected for further experimentation and hereafter 
are referred to as ∆ThhepA::hph1, ∆ThhepA::hph2 and ∆ThhepA::hph3.  
 
Figure 10 | Confirmation of hepA deletion via DIG-Southern blot analysis. 
Genomic DNA was extracted from putative hepA deletion mutants and 
subsequently digested using restriction enzyme StuI. A DIG-labelled left flank 
probe was created to probe for wild-type strains (3201 bp) and hepA deletion 
strains (6811 bp). Lane 1; Fermentas GeneRuler 1 Kb ladder, lane 2; GD12 
genomic DNA, lanes 3-10; putative hepA deletion mutants. 
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3.4 Phenotypic analysis of ∆ThhepA::hph strains 
3.4.1 Loss of HEP1 leads to growth inhibition 
Phenotypic analysis of the ∆ThhepA::hph strains was carried out on PDA plates 
under both light and dark conditions. Hyphal growth was recorded over a 10-
day period by scanning each plate with an Epson Perfection V750 Pro scanner 
and images analysed using imageJ. The three independent ∆ThhepA::hph 
strains all showed significantly compromised hyphal growth compared with the 
wild-type strain GD12 (Figure 11-1). Growth of the mutants was sporadic, with 
hyphal proliferation below the agar surface. The wild-type strain GD12, 
however, grew in a more consistent manner, with an even distribution, reaching 
the edge of the agar plate within 4 – 5 days (Figure 11-2). These findings are 
consistent with a spore count carried out on PDA plates grown in light and dark 
conditions for 14 days (Figure 11-3). The ∆ThhepA::hph mutants had a 
significantly reduced spore count, compared with the wild-type, under both light 
(Figure 11-3A) and dark (Figure 11-3B) growth conditions. 
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Figure 11 | Phenotypic analysis of hepA mutants. Loss of HEP1 leads to growth 
inhibition of mutant strains (1: A – wild-type GD12, B - ∆ThhepA::hph1, C - 
∆ThhepA::hph2, D - ∆ThhepA::hph3. Analysis of growth rates on PDA plates in light 
(2A) and dark (2B) shows mutants have significantly reduced growth compared to 
GD12 over a 10 day growth period. Bars are the means of replicates ± standard 
errors. This is consistent with spore counts at 14 d.p.i. (3A – light, 3B – dark) with 
hepA mutants producing significantly fewer spores. Bars are the means of 
replicates ± standard errors. Two-way ANOVA and post-hoc Tukey tests show 
significant differences (p<0.05) indicated by different letters. 
45 
 
 
3.4.2 Loss of HEP1 leads to changes in antimicrobial activity 
To investigate antimicrobial activities concomitant with loss of HEP1, 
confrontation plates were established by inoculating the upper half of a PDA 
plate with T. hamatum and the lower half with a range of both plant and human 
pathogens. When T. hamatum GD12 was confronted with a range of plant 
pathogenic fungi and oomycetes, the wild-type strain rapidly overgrew the 
pathogens. (Figure 12). In contrast, ∆ThhepA::hph mutants displayed antibiosis 
producing a zone of inhibition surrounding mutant colonies. 
Confrontation assays were also performed with a range of multidrug resistant 
human pathogenic yeasts. The wild-type strain GD12 similarly overgrew the 
yeasts, whereas ∆ThhepA::hph strains displayed a zone of growth inhibition 
(Figure13).
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Figure 12 | Broad-spectrum inhibition of pathogenic fungi and oomycetes. The upper half of PDA plates were inoculated with wild-
type T. hamatum GD12 (top row) and three independent hepA deletion mutants ∆ThhepA::hph1, ∆ThhepA::hph2 and ∆ThhepA::hph3 
(bottom three rows respectively). The lower half of the PDA plates were inoculated with various plant pathogenic fungi. After 5 days 
growth, the interactions between T. hamatum strains and pathogens were recorded. T. hamatum GD12 displays inhibition of the 
pathogens by hyphal overgrowth. Loss of HEP1, however, results in a zone of inhibition (antibiosis) of the pathogens.
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Figure 13 | Broad spectrum inhibition of multi-drug resistant human pathogenic yeasts. The upper half of PDA plates were 
inoculated with wild-type T. hamatum GD12 (top row) and three independent hepA deletion mutants ∆ThhepA::hph1, ∆ThhepA::hph2 
and ∆ThhepA::hph3 (bottom three rows respectively). T. hamatum strains were allowed to grow for 3 days before any un-colonised area 
of the plates were streaked with a range of human pathogenic yeasts. Strains were allowed to grow for a further 2 days before 
interactions were recorded. T. hamatum GD12 displays inhibition of the pathogens by hyphal overgrowth .Loss of HEP1, however, results 
in a zone of inhibition (antibiosis) of the pathogens. 
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3.4.3 Loss of HEP1 leads to an altered secretome 
To determine if loss of HEP1 leads to an altered metabolome, samples were 
taken from the media surrounding of the leading edge of actively growing fungi. 
Samples consisted of; ∆ThhepA::hph2 and S. sclerotiorum M448 independent 
strains, as well as the uncolonised media from confrontation and inhibition 
zones of T. hamatum GD12 and ∆ThhepA::hph2, respectively, when confronted 
with S. scleroriorum M448 (2 d.p.i). A non-inoculated PDA plate was also 
analysed and any features present in the sample were considered background 
and subsequently removed from all other sample sets.  
When data is visualised as a heat map, feature clustering is consistent between 
replicates for each treatment type, both in positive ionisation mode (Figure 14 
A) and negative ionisation mode (Figure 14 B). Multiple features are up- and 
down- regulated differentially between treatment types, yet others are 
constitutively expressed. 
Visualising the data through Venn diagrams (Figure 15) shows clear clustering 
of features. The number of ‘core’ features in both data sets is very low, with 26 
shown in positive ionisation mode and only 4 with negative ionisation. Loss of 
HEP1 leads to constitutive expression of 45 positive ionisation features and 30 
negative. Interestingly, 301 positive and 125 negative ionisation features are 
unique to the ∆ThhepA::hph2 sample, whereas a further 95 positive and 116 
negative ionisation features are only expressed when ∆ThhepA::hph2 is 
confronted with S. sclerotiorum M448. Deletion of hepA leads to the loss of 82 
positive and 100 negative ionisation features which are only present during T. 
hamatum GD12 confrontation with S. sclerotiorum M448. Ionisation features 
which are considered ‘core’ to the T. hamatum secretome indicate 23 positive 
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Figure 14 | Heat maps showing differential fingerprint clustering of secreted compounds produced by T. hamatum and S. 
sclerotiorum M448.  Samples containing secreted compounds were taken from the inhibition/interaction zone of confrontation plates, 
or from media surrounding the leading edge of actively growing independent cultures and were run twice on an LC-MS with a polaris 
C18 reversed phase column (once in positive ion mode (A) and once in negative (B)) on QTOF using electrospray ionisation. Features 
which were found in two out of three of the replicates were considered genuine. Clustering within each of the treatment types is 
consistent and differential expression is seen between the individual treatment types. 
A B 
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and 11 negative features, which are present across all T. hamatum strains 
whether they are confronted with S. sclerotiorum or not. However, features 
present only when T. hamatum strains are confronted with S. sclerotiorum 
reveals 17 positive and 15 negative. From here we began an attempt to identify 
some key features secreted by ∆ThhepA::hph2 which may display antimicrobial 
activities. Due to two of the sample vials becoming damaged whilst being 
analysed on the LC-MS, replicates 2 of GD12-M448 and ∆ThhepA::hph-M448 
were removed. 
Key features were normalised to the internal standard, umbelliferone, and 
relative abundance presented as bar charts.  Positive ionisation data (Figure 
16) revealed an interesting array of key features, many of which had 
characteristic pharmaceutical potential. Dibenzo-quinoline carbaldehyde 
(Figure 16 A) was highly expressed in PDA with lower levels of expression 
present in all other samples, particularly GD12-M448. Levels of tetrahydro-
quinoline carbaldehyde (Figure 16 B) were abundant in samples containing 
hepA mutants, but did not appear to be present, at least not in significant 
abundance, in all other samples. Brefeldin A (Figure 16 C) and adephenine 
(Figure 16 F) were in low abundance in S. sclerotiorum M448 only samples, in 
high abundance when in confrontation with hepA mutants, but absent when in 
confrontation with the wild-type GD12. Norcantharidin (Figure 16 D), 
kynurenic acid (Figure 16 E) and 1-methyl-2-pyrrolidone (Figure 16 G) were 
only present in samples containing hepA mutants, and were particularly 
abundant when in confrontation with S. sclerotiorum M448. Low levels of 
desthiobiotin (Figure 16 I) were recorded when GD12 was confronted with S. 
sclerotiorum M448 and when hepA mutants were grown independently, with 
slightly higher levels being presented in all other samples. Constitutively low 
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levels of (s)-(-)-perillic acid expression were displayed across all sample sets, 
with the exception of hepA mutants confronted with S. sclerotiorum M448 where 
elevated levels were shown. 
Analysis of key negative ion features showed constitutively high levels of 4-
hydroxy-3-methoxybenzoate expression (Figures 17 B (3.8 min RT), C (4.3 
min RT) and D (8.8 min RT)) in all samples containing hepA mutants, but was  
absent from all other sample sets. Levels of camptothecin (Figure 17 A) and 
sebacate (Figure 17 G) were low across all samples, with slightly elevated 
expression in samples containing hepA mutants, particularly in hepA mutants as 
independent cultures. Confrontation samples of ∆ThhepA::hph with S. 
sclerotiorum M448 displayed elevated abundance levels of N-
methylanthranilate (Figure 17 E), with slightly lower levels displayed in 
∆ThhepA::hph only samples. However, it was absent from all other treatments. 
Phenylalanine (Figure 17 H) was relatively abundant across all sample sets, 
with lower levels expressed in S. sclerotiorum M448 only samples, and when in 
confrontation with GD12. Independent ∆ThhepA::hph strains displayed the 
lowest levels of phenylalanine. Low levels of 2-deoxyribose 5-phosphate 
(Figure 17 F) were recorded in PDA, S. sclerotiorum M448 and ∆ThhepA::hph 
samples, with slightly higher levels found in confrontation samples. 
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Figure 15 | Venn diagrams showing clustering of secreted features identified by using LC-MS (QTOF) analysis. Data from 
positive ionisation (A) and negative ionisation (B) heat maps (Figure 14) was converted into Venn diagrams to visualise differentiation 
of secreted compounds. Blue represents S. sclerotinia M448 only, yellow represents ∆ThhepA::hph2 only, green represents T. 
hamatum GD12 confronted with S. sclerotiorum M448 and red represents ∆ThhepA::hph2 confronted with S. sclerotiorum. As all 
strains were grown on PDA, any features found in the PDA only sample were considered background and were subsequently removed 
from all other data sets. 
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Figure 16 | Key features identified from positive ionisation samples. 
Treatment types are as follows: GD12-M448 (blue), ∆ThhepA::hph (red), 
∆ThhepA::hph-M448 (green), PDA (orange) and M448 (purple). (A) Dibenzo-
quinoline carbaldehyde; (B) Tetrahydro-quinoline carbaldehyde – used in the 
production of photosensitive materials; (C) Brefeldin A – an antimicrobial 
agent; (D) Norcantharidin – conveys anticancer properties; (E) Kynurenic 
acid – an anticonvulsant; (F) Adephenine – a smooth muscle relaxant; (G) 1-
Methyl-2-pyrrolidone – used in the recovery of pure hydrocarbons; (H) (S)-(-)-
Perillic acid – a hypoglycemic agent used as an anti-diabetic; (I) Desthiobiotin 
– an immunosuppressive agent.  
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Figure 17 | Key features identified from negative ionisation samples. 
Treatment types are as follows: GD12-M448 (blue), ∆ThhepA::hph (red), 
∆ThhepA::hph-M448 (green), PDA (orange) and M448 (purple). (A) 
Campothecin – inhibits topoisomerase I; (B, C and D) 4-Hydroxy-3-
methoxybenzoate – a precursor for Vanillin, a vanilla bean extract; (E) N-
Methylanthranilate – the starter unit of acridone alkaloid biosynthesis, 
bioactive property as an antimalarial drug; (F) 2-Deoxyribose 5-phosphate – 
catalyzes the reverse aldol condensation reaction without any cofactors; (G) 
Sebacate – used in the manufacturing of polymer plastics; (H) Phenylalanine 
– function unclear, potential use as a pharmacological agent.  
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4. Discussion 
As the human population increases and alternative approaches to sustainable 
agricultural intensification are sought, identifying new sources of bioactive 
compounds that promote plant productivity and inhibit plant and humans 
pathogenic fungi is of major importance for both food security and for human 
health. 
This project set out to determine whether deletion of HEP1 in the plant-growth-
promoting and biocontrol fungus T. hamatum GD12 might lead to activation of 
cryptic secondary metabolite gene clusters and concomitant secretion of novel 
bioactive compounds with antimicrobial activities. Indeed, results show that loss 
of the HEP1 protein leads to altered antimicrobial activity with simultaneous 
changes in the fungal secretome. These findings directly correlate to the 
differential fingerprint clustering derived from LC-MS analysis. 
Bioinformatics analysis of HEP1 indicates high levels of conservation of GD12 
with T. atroviride (87.64% homology). The chromo and chromo-shadow 
domains are particularly highly conserved when compared with other eukaryotic 
organisms, suggesting the function of HEP1 in T. hamatum GD12 is consistent 
with that of other eukaryotic organisms. Binding of the chromo domain to di- and 
tri- methylation residues on H3K9 is achieved by three conserved amino acids, 
Tyr-24, Trp-45 and Tyr-48 in Drosophila, creating a hydrophobic cage acting as 
the binding site. The latter two of these amino acids are conserved in GD12, 
however, the former appears to be either misaligned, or a SNP has modified the 
UAC codon which translates to Tyr into UUC which conferring Phe. Further 
investigation would be required to determine the exact structure of the T. 
hamatum homolog. Nevertheless, investigations conducted here suggest a 
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function of the protein in chromatin re-modelling and regulation of secondary 
metabolite gene clusters. 
Altered antimicrobial activity as a consequence of altered gene cluster 
regulation was established through confrontation assays against a range of both 
agriculturally and medically important pathogens (displaying multiple host range 
and multidrug resistance, respectively), with loss of HEP1 leading to aberrant 
growth of mutants, and antibiosis of pathogens. Analysis of the small molecule 
secretome via LC-MS analysis suggests HEP1 may be a ‘hub’ gene, with 
involvement in multiple pathways. Many features from both positive and 
negative ionisation data sets are differentially up- and down- regulated due to 
loss of HEP1. Interestingly, however, 82 positive and 100 negative features are 
present when T. hamatum GD12 is confronted with S. sclerotiorum M448 which 
are not present in any other samples, suggesting that HEP1 is indeed involved 
in multiple pathways and either the protein itself or bioactive product(s) derived 
from the pathway may subsequently repress other SM gene clusters. However, 
confirmation of this hypothesis would require further investigation. 
Key features identified from both positive and negative ion LC-MS data reveal a 
broad range of differentially secreted proteins. Constitutively high levels of (S)-(-
)-perillic acid (causing growth inhibition and protein prenylation of cancer cells49) 
and 4-hydroxy-3-methoxybenzoate (RT; 3.8 min, 4.3 min and 8.8 min – 
bioactive characteristics uncharacterised) are expressed in samples containing 
hepA mutants, with levels of expression decreasing as retention time increases 
for the latter. This may suggest HEP1 is a key regulator of the biosynthetic 
pathways from which these compounds are derived. Other data suggests HEP1 
is a regulator of N-methylanthranilate (a bird repellent used on grasses50 which 
is also found in grapes51), kynurenic acid (a product of L-tryptophan metabolism 
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with high levels found in patients suffering from tick-borne encephalitis52 and 
schizophrenia53), 1-methyl-2-pyrrolidone (used in the recovery of hydrocarbons 
from petrochemical processing54 but has recently been identified as a 
reproductive toxicant55) and norcantharidin (a demethylated analogue of the 
natural toxin – cantharidin, shown to inhibit growth of tumors56) are only present 
through deletion of hepA, but are further upregulated when ∆ThhepA::hph 
strains are confronted with S. sclerotiorum M448. These findings suggest HEP1 
does indeed play a role in regulation of gene clusters. However, some identified 
compounds are further up-regulated during confrontation with S. sclerotiorum 
M448, suggesting other regulatory proteins may also play a key role in the 
biosynthesis of product(s) derived from the pathway(s). Camptothecin is a 
topoisomerase I inhibitor57 which has been utilised for anticancer treatment58 
and is found in abundance in ∆ThhepA::hph samples, with slight down-
regulation when in confrontation with S. sclerotiorum M448. A similar pattern is 
seen with sebacate (used in the production of polymers for targeted drug 
delivery59). 
All of the above compounds are unique to samples containing ∆ThhepA::hph 
strains, supporting the hypothesis that hepA may be a ‘hub’ gene with 
involvement in multiple pathways. Another identified feature of particular interest 
is Brefeldin A, which is highly abundant when ∆ThhepA::hph is confronted with 
S. sclerotiorum M448, but absent from all other sample sets. This lactone 
antibiotic inhibits GBF1 (guanine nucleotide exchange factor) causing 
movement of secretory proteins from the golgi into the endoplasmic reticulum 
(ER) which in turn activates ER stress and results in apoptosis60,61. When 
considering the mutant-pathogen confrontation assays, a clear zone of inhibition 
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is displayed surrounding the leading edge of ∆ThhepA::hph cultures. Secretion 
of Brefeldin A could provide an explanation for this phenotype.  
Due to increased demand for novel bioactive compounds62–64, successful 
identification and application would prove beneficial. Compounds effective as 
fungicides against plant diseases should ideally provide systemic resistance. 
Brefeldin A was shown to be highly upregulated in ∆ThhepA::hph + S. 
sclerotiorum M448 LC-MS samples inhibits membrane transport and is 
therefore toxic to eukaryotic cells and would not be a useful candidate60,65. 
Over use of antibiotics has led to an increase in drug-resistant fungal pathogens 
and the emergence of fungal pathogens with intrinsic resistance to mould-active 
compounds, means that novel antifungal compounds are urgently needed to 
control opportunistic fungal infections in the ever-increasing population of 
immunocompromised patients63. With no new antifungal drugs on the 
immediate horizon and with azole resistance now becoming widespread in 
hospitals, identification of novel antimicrobial compounds would therefore be of 
enormous benefit to medicine by providing alternatives to the azoles, 
echinocandins and polyenes that inhibit fungal cell wall biosynthesis and which 
display varying activities against fungi capable of causing human infections. 
Further investigations of the regulatory pathways governing secondary 
metabolite biosynthesis in naturally occurring soil fungi such as Trichoderma 
spp. may allow the discovery of previously uncharacterised antimicrobial 
compounds with new modes of action 
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4.1  
 
4.1 Concluding remarks and future investigation 
Loss of HEP1 has a significant impact on the growth and development of T. 
hamatum GD12, an alteration in the biocontrol capabilities of the fungus, and 
most significantly an alteration to the secretome. 
This project has begun to investigate bioactive product(s) derived from the 
biosynthetic pathway in which HEP1 is a regulatory component. The research 
has also indicated the possible involvement of the HEP1 protein in additional 
regulatory pathways. The project could have benefited from RT-PCR to 
determine the effects that the loss of HEP1 has on other genes involved in 
secondary metabolite biosynthesis. This might also identify other potential 
genes of interest that have a significant role in the production of secondary 
metabolites. Demonstrating antibiosis of pathogens using metabolite extracts, 
lacking the presence of actively growing T. hamatum, would confirm the 
phenotype displayed is caused by stable secretion compounds, and that the 
presence of T. hamatum is not required for its function. 
All confrontation assays conducted within this study were carried out on PDA, 
however, this alone may have a significant impact on the efficacy of 
Trichoderma to display biocontrol properties. Therefore, investigating this 
phenotype on a range of minimal and rich media would allow a better 
understanding. 
Furthermore, the zone of inhibition phenotype portrayed by the mutant strains 
may include an element of autolysis. This may be investigated through 
microscopy and/or release of a cytoplasmic marker enzyme. 
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Creation of a complemented strain of ∆ThhepA::hph2 would confirm that the 
phenotypes displayed by loss of HEP1 are due to loss-of-function, by restoring 
the phenotype displayed by the wild-type through re-insertion of hepA into the 
genome. Although previous attempts have proved this to be difficult due to lack 
of an additional selectable marker, further study would clearly benefit from such 
a strain and investigation into other transformation techniques may yield more 
success in this area. 
Analysis of the secretome by LC-MS has begun to reveal some interesting 
results. Testing the biocontrol activities of the identified key features would 
significantly benefit this study. Also, analysis of a T. hamatum GD12 only 
sample set would allow confirmation of constitutive expression from 
∆ThhepA::hph2 which is not present in the wild-type. However, the focus of this 
project was to identify novel antimicrobial compounds and therefore, a GD12 
only sample set was not investigated. All of the above mentioned compounds 
were isolated and identified from a methanol extraction method, however, this 
may limit detection of more hydrophobic compounds. Further investigation may 
benefit from a chloroform extraction also, for further identification of non-polar 
compounds. 
Overall, this project has demonstrated that genetic modification is a useful 
resource for the identification of novel compounds, and the data and resources 
generated from this study constitutes a strong foundation for further research 
into this subject area. 
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6. Appendices 
6.1 List of primers used for cloning 
Primer Sequence 
hepA_LF-LP 5'-TGTAGACTGCTGCAGTGCACAA-3' 
hepA_LF_LP2 5'-CACCTCGCACTGTATACTGGT-3' 
hepA_LF-RP 5'-gtcgtgactgggaaaaccctggcgTGCAACGATGAGAAGCGATTGGT-3' 
hepA_RF-LP 5'-tcctgtgtgaaattgttatccgctACTCAAGTGAGAAGACGTCGGA-3' 
hepA_RF-RP 5'-ACACGATAAATGTGCCCGTCCT-3' 
M13.LP 5'-TCCTGTGTGAAATTGTTATCCGCTGCCAGCATCCAA-3' 
M13.RP 5'-GTCGTGACTGGGAAAACCCTGGCGGACGCCATACTC-3' 
HY-split 5'-GGATGCCTCCGCTCGAAGTA-3' 
YG-split 5'-CGTTGCAAGACCTGCCTGAA-3' 
 
6.2       Conditions for polymerase chain reaction 
  
Product 
Product 
size (bp) 
Primer name Template 
Annealing 
temperature 
Extension 
time 
hepA 
ORF 
1118 
hepA_ORF_LP GD12 
genomic 
DNA 
52°C 1 min 
hepA_ORF_RP 
1
s
t  
ro
u
n
d
 P
C
R
 
hepA LF 1016 
hepA_LF_LP GD12 
genomic 
DNA 
52°C 1 min 
hepA_LF_RP 
hepA RF 940 
hepA_RF_LP GD12 
genomic 
DNA 
52°C 1 min 
hepA_RF_RP 
HY 1200 
M13_LP hph 
cassette 
58°C 
1 min 10 
sec HY_split 
YG 800 
YG_split hph 
cassette 
58°C 
1 min 10 
sec M13_RP 
2
n
d
 r
o
u
n
d
 P
C
R
 
hepA LF 
+ HY 
2216 
hepA_LF_LP hepA LF 
+ HY 
62°C 
2 min 15 
sec HY_split 
hepA RF 
+ YG 
1740 
YG_split hepA RF 
+ YG 
62°C 
1 min 50 
sec hepA_RF_RP 
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6.3 Gel images of PCR products and genomic digests. 
All images are of 0.8 % TAE agarose gel, unless stated otherwise. All are 
against 10 µl Fermentas GeneRuler 1 Kb ladder, unless stated otherwise. (A) 5 
µl GD12 genomic DNA, flanked by 5 µl of 1 kb ladder, run on a 1.2 % TAE 
agarose gel; (B) 9 x 25 µl LF PCR reactions, plus 1 x 25 µl H2O control; (C) 9 x 
25 µl RF PCR reactions, plus 1 x 25 µl H2O control; (D) 5 x 25 µl HY PCR 
reactions, plus 1 x 25 µl H2O control; (E) 5 x 25 µl YG PCR reactions, plus 1 x 
25 µl H2O control; (F) 27 x 25 µl LF+HY second round fusion PCR reactions, 
plus 1 x 25 µl H2O control, (G) 27 x 25 µl RF+YG second round fusion PCR 
reactions, plus 1 x 25 µl H2O control, (H) 20 µg of putative hepA deletion 
mutants, digested with restriction enzyme StuI, run on a 1 % TBE agarose gel.  
A B 
C 
D 
E 
F G 
H 
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6.3 T. hamatum GD12 antiSMASH output 
        TRICHODERMA ATROVIRIDE IMI206040 ASPERGILLUS NIDULANS FGSC_A4 
CLUSTER Type Contig_Orf Location BLAST
P  (E-
Value) 
Annotation BLAST
P  (E-
Value) 
Annotation 
1 
N
r
p
s
 
Ctg148_Orf000000 3048-46215 0 Non-Ribosomal Peptide 
Synthetase (Β-Ketoacyl 
Synthase) 
5E-169 Hypothetical Protein (Sidn3-Like) 
(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
Ctg148_Orf000001  46569-47957 0 Hypothetical Protein (Ppx/Gppa 
Phosphatase Family) 
2E-118 Retrograde Regulation Protein 2 
(AFU_Orthologue)(Ppx/Gppa 
Phosphatase Family) 
Ctg148_Orf000002  53737-55559 0 Hypothetical Protein (Lysp - 
Amino Acid Transporter And 
Metabolism) 
0 Prnb (Proline-Specific 
Permease) 
Ctg148_Orf000003  56578-57148 5E-99 Hypothetical Protein (Β-CA-
Claded) Carbonic Anyhydrase 
1.1 Hypothetical Protein (Β-CA-
Claded) Carbonic Anyhydrase 
Ctg148_Orf000004  61401-61949 1.8  3.6   
Ctg148_Orf000005 64211-65303 0 Hypothetical Protein (Aldo-Keto 
Reductases (Akrs)) 
4e-139 Aflatoxin B1-Aldegyde 
Reducatse (Gli0-Like) 
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Ctg207_Orf000000 3837-5107 4e-56 Non-Ribosomal Peptide 
Synthetase (Sidn3-Like) 
(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
3e-50 Hypothetical Protein (Sidn3-Like) 
(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
Ctg207_Orf000001 12776-13278 6e-27 Non-Ribosomal Peptide 
Synthetase (Sidn3-Like) 
(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
1e-23 Hypothetical Protein (Sidn3-Like) 
(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
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Ctg207_Orf0002 13941-14134 7.1 Hypothetical Protein (SRR1) 2.7 Putative Zn(II)2Cys6 
Transcription Factor (GAL4) 
Ctg207_Orf003 17639-17864 5.3 Hypothetical Protein (Mvim - 
Predicted Dehydrogenases And 
Related Proteins) 
0.97 Hypothetical Protein (NAD 
Binding 8 - NAD(P)-Binding 
Rossmann-Like Domain) 
Ctg207_Orf04 18184-18402 2.7 Hypothetical Protein (Peptidase 
S24 S26 - Lexa/Signal 
Peptidase Superfamily) 
2.3 Cytochrome P450, Putative 
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Ctg221_Orf000000 1386-2880 0.85 Hypothetical Protein 
(Transcription Factor Involved In 
Chromatin Remodeling- N-
Acyltransferase Superfamily) 
6.9 Hypothetical Protein (Polyletide 
Synthase Modules And Related 
Proteins) 
Ctg221_Orf00001 5833-6057 0.17 Hypothetical Protein 0.072 Hypothetical Protein (Predicted 
Acyl-Coa Transferases/Carnitine 
Dehydratase) 
Ctg221_Orf0002 6547-6805 7e-28 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
4.7 Hypothetical Protein (Anp1) 
Ctg221_Orf003 7369-8458 3e-67 Hypothetical Protein 
(Cytochrome P450) 
6e-44 Hypothetical Protein 
(Cytochrome P450) 
Ctg221_Orf04 11673-12667 0 Hypothetical Protein (Caic - 
Acyl-Coa Synthetases (AMP-
Forming)) 
7e-12 Conserved Hypothetical Protein 
(AMP-Binding/Adenylate 
Forming Domain, Class I) 
Ctg221_Orf5 18912-19659 2e-41 Hypothetical Protein (Caic - 
Acyl-Coa Synthetases (AMP-
Forming)) 
0.24 Hypothetical Protein (FHA - 
Forkhead Associated Domain) 
Ctg221_Orf6 19674-20349 7e-86 Hypothetical Protein 
(Condensation Domain) 
6e-11 Hypothetical Protein 
(Condensation Domain) 
Ctg221_Orf7 18912-19659 7e-140 Hypothetical Protein (Prtases-
Type I - Phosphoribosyl 
Transferase (PRT)-Type I 
Domain) 
1e-97 Xanthine-Guanine 
Phosphoribosyl Transferase 
(Xpt1), Putative (PRT-Type I 
Domain) 
Ctg221_Orf8 19674-20349 9.9 Hypothetical Protein (Tht1-Like 
Nuclear Fusion Protein) 
3.3 Hypothetical Protein (Kelch 5 
Motif) 
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Ctg235_Orf000000 2741-3428 5e-47 Non-Ribosomal Peptide 
Synthetase (Condensation 
Domain) 
2e-48 Hypothetical Protein (Sidn3-Like) 
(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
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Ctg322_Orf000000 2345-2733 8.3 Hypothetical Protein (IDO - 
Indoleamine 2,3-Dioxygenase) 
2.3 Hypothetical Protein (Thif - 
Dinucleotide-Utilizing Enzymes 
Involved In Molybdopterin And 
Thiamine Biosynthesis Family 2) 
Ctg322_Orf00001 6729-7971 0 Polyketide Synthase (Β-Ketoacyl 
Synthase) 
6e-112 Hypothetical Protein (PKS - Β-
Ketoacyl Synthase) 
Ctg322_Orf0002 12589-15508 0 Hypothetical Protein (Caic - 
Acyl-Coa Synthetases (AMP-
Forming)) 
0 Hypothetical Protein (Caic - 
Acyl-Coa Synthetases (AMP-
Forming)) 
Ctg322_Orf003 16812-18876 0 Hypothetical Protein (NAD 
Binding 8 - NAD(P)-Binding 
Rossmann-Like Domain) 
2e-115 Conserved Hypothetical Protein 
(NAD Binding 8 - NAD(P)-
Binding Rossmann-Like Domain) 
Ctg322_Orf04 19806-20249 9e-86 Hypothetical Protein (PT Ubia 
COQ2, 4-Hydroxybenzoate 
Polyprenyltransferase) 
9e-18 Hypothetical Protein (PT Ubia 
COQ2, 4-Hydroxybenzoate 
Polyprenyltransferase) 
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Ctg402_Orf000000 918-1451 1e-13 Putative Epoxide Hydrolase 
(Abhydrolase 6) 
2.5 Hypothetical Protein (MFS - 
Major Facilitator Superfamily) 
Ctg402_Orf00001 1725-2867 0 Hypothetical Protein (ZIP Zinc 
Transporter) 
7e-169 Hypothetical Protein (ZIP Zinc 
Transporter) 
Ctg402_Orf0002 5568-6952 1.4 Multidrug Resistance-Like 
Protein (MRP Assoc Pro) 
0.62 Hypothetical Protein (Glycine 
Dehydrogenase; Provisional) 
Ctg402_Orf003 13102-14756 0 Hypothetical Protein (Lysp - 
Amino Acid Transport And 
Metabolism) 
9e-180 Basic Amino Acid Transporter 
(Lysp - Amino Acid Transport 
And Metabolism) 
Ctg402_Orf04 16146-19994 0 Non-Ribosomal Peptide 
Synthetase (Adenylation 
Domain) 
0 Hypothetical Protein 
(Adenylation Domain) 
Ctg402_Orf5 21469-23586 0 Hypothetical Protein 
(Arylsulfotransferase (ASST)) 
5e-54 Hypothetical Protein 
(Arylsulfotransferase (ASST)) 
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Ctg402_Orf6 24066-25549 1e-52 Hypothetical Protein (Rdrp - 
RNA Dependent RNA 
Polymerase) 
0.094 Hypothetical Potein (Putative 
Methyltransferase) 
Ctg402_Orf7 28262-30976 0 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
5e-15 Putative Zn(II)2Cys6 
Transcription Factor (GAL4) 
Ctg402_Orf8 31620-33356 0 Hypothetical Protein (RIO1 - 
Serine/Threonine Protein Kinase 
Involved In Cell Cycle Control) 
0 Hypothetical Protein (RIO1 - 
Serine/Threonine Protein Kinase 
Involved In Cell Cycle Control) 
Ctg402_Orf9 33877-34175 0.34 Iron Sulfur Cluster Assembly 
Protein (Iscu-Like) 
4.5 Conserved Hypothetical Protein 
(Protein Of Unknown Function) 
Ctg402_Orf10 34598-36026 0 Hypothetical Protein (Asp - 
Eukaryotic Aspartyl Protease) 
1e-67 Hypothetical Protein (Asp - 
Eukaryotic Aspartyl Protease) 
Ctg402_Orf11 36550-37575 0 Hypothetical Protein (PCBER 
SDR A - Phenylcoumaran 
Benzylic Ether Reductase Like) 
4e-63 Hypothetical Protein (NADB 
Rossmann) 
Ctg402_Orf12 37638-38198 4.0 Hypothetical Protein 0.66 Hypothetical Protein (NAD 
Binding 8 - NAD(P)-Binding 
Rossmann-Like Domain) 
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Ctg512_Orf0002 5984-7219 5e-71 Hypothetical Protein (Protein Of 
Unknown Function) 
5e-17 Hypothetical Protein (Protein Of 
Unknown Function) 
Ctg512_Orf003 8817-10776 0 Hypothetical Protein (F-Box-
Like) 
0.082 Hypothetical Protein (F-Box-
Like) 
Ctg512_Orf04 11191-13407 0 Glycoside Hydrolase Family 20 
Protein (Glyco Hydro 20b) 
6e-92 Hypothetical Protein (Glyco 
Hydro 20b) 
Ctg512_Orf5 17272-20424 0 Hypothetical Protein (Peptidases 
S8 5) 
0.007 Hypothetical Protein (Peptidases 
S8 Protein Convertases Kexins 
Furin-Like) 
Ctg512_Orf6 23960-24555 1e-118 Hypothetical Protein (GFA - 
Glutathione-Dependent 
Formaldehyde-Activating 
Enzyme) 
4e-70 Hypothetical Protein (GFA - 
Glutathione-Dependent 
Formaldehyde-Activating 
Enzyme) 
Ctg512_Orf7 24814-32496 0 Polyketide Synthase (Acyl 
Transferase Domain) 
0 Hypothetical Protein 
(Acyltransferase Domain In PKS 
Enzymes) 
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Ctg512_Orf8 34275-34924 1e-40 Hypothetical Protein (FSH1 - 
Serine Hydrolase) 
2e-06 DUF341 Family Oxidoreductase, 
Putative (Serine Hydrolase 
(FSH1)) 
Ctg512_Orf9 35114-35472 7.5 Hypothetical Protein (Aldo-Keto 
Reductases (Akrs)) 
1.9 Hypothetical Protein (Stkc 
Phototrophin-Like Protein) 
Ctg512_Orf10 36187-37811 0 Glycosyltransferase Family 
Protein 1 
2e-76 UDP-Glucoronosyl And UDP-
Glucosyl Transferase Family 
Protein 
Ctg512_Orf11 47529-48803 0 Hypothetical Protein (SWIRM 
Domain) 
3e-46 SWIRM Domain Protein Fun19, 
Putative 
Ctg512_Orf12 51277-55040 0 Hypothetical Protein 
(Chromosomal Segregation 
Atpases) 
1e-66 Hypothetical Protein (RIM-
Binding Protein Of The 
Cytomatrix Active Zone) 
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Ctg634_Orf000000 1330-1763 8e-68 Hypothetical Protein (Stress 
Responsive A/B Barrel Domain) 
1e-27 Hypothetical Protein (Stress 
Responsive A/B Barrel Domain) 
Ctg634_Orf00001 2298-2252 1e-64 Hypothetical Protein 
(Uncharacterized Protein 
Containing Double-Stranded 
Beta Helix Domain) 
1e-59 Hypothetical Protein 
(Uncharacterized Protein 
Containing Double-Stranded 
Beta Helix Domain) 
Ctg634_Orf0002 3327-4851 8e-81 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
4e-07 Hypothetical Protein (Ubih - 2-
Polyprenyl-6-Methoxyphenol 
Hydoxylase And Related FAD-
Dependent Oxidoreductases) 
Ctg634_Orf003 6543-7148 9.5 Hypothetical Protein (MOR2-
PAG1 N) 
3.7 Hypothetical Protein (CYCLIN) 
Ctg634_Orf04 9245-12169 0 Polyketide Synthase-Like 
Protein (Β-Ketoacyl Synthase) 
5e-172 Polyketide Synthase, Putative 
(Acyl Transferase Domain In 
Polyketide Synthase) 
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Ctg665_Orf27 106307-
108867 
0 Hypothetical Protein (CNH 
Domain) 
0 Hypothetical Protein (CNH 
Domain) 
Ctg665_Orf28 109276-
117495 
0 Hypothetical Protein (Multidrug 
Resistance Protein (Mdr1)) 
0 Hypothetical Protein (Multidrug 
Resistance Protein (Mdr1)) 
Ctg665_Orf29 118280-
120555 
0 Hypothetical Protein (Trxb - 
Thioredoxin 
Reductase(Posttranslation 
Modification)) 
1e-119 Hypothetical Protein (Trxb - 
Thioredoxin 
Reductase(Posttranslation 
Modification)) 
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Ctg665_Orf30 121172-
123777 
2e-121 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
1e-58 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
Ctg665_Orf31 125360-
126796 
0 Hypothetical Protein 
(Acetyltransferase Domain) 
1e-114 Hypothetical Protein 
(Acetyltransferase Domain) 
Ctg665_Orf32 126998-
129880 
0 Long-Chain-Fatty-Acid-Coa 
Ligase 
3e-125 Acyl Coa Synthetase 
Ctg665_Orf33 130614-
136053 
0 Hypothetical Protein (Sidn3-
Like)(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
6e-164 Hypothetical Protein (Sidn3-
Like)(Adenylation (A) Domain Of 
Siderophore-Synthesizing 
Nonribosomal Peptide 
Synthetases) 
Ctg665_Orf34 136631-
139527 
5e-167 Hypothetical Protein (Protein Of 
Unknown Function) 
3e-17 Hypothetical Protein (Protein Of 
Unknown Function) 
Ctg665_Orf35 144060-
145115 
0.39 Hypothetical Protein (Ribosomal 
P1 P2 L12p) 
6.6 Hypothetical Protein (GET 
Complex Subunit GET2) 
Ctg665_Orf36 146362-
147937 
0 Hypothetical Protein (PAP-1-
Like Conserved Region) 
2e-13 Hypothetical Protein (PAP-1-Like 
Conserved Region) 
Ctg665_Orf37 148310-
148453 
0.18 Hypothetical Protein 
(Flavokinase) 
0.20 Hypothetical Protein (Sulfur 
Sfnb) 
Ctg665_Orf38 149978-
151129 
0 Peroxisomal Membrane Anchor 
Domain-Containing Protein, 
Varient 1) 
3e-46 Hypothetical Protein 
(Peroxisomal Membrane Anchor 
Protein (Pex14_N) 
Ctg665_Orf39 153788-
153969 
     
Ctg665_Orf40 154417-
158953 
0 Hypothetical Protein (BRX1) 4e-114 Ras Gtpase Similar To RAB11B 
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Ctg699_Orf000000 27-1806 0 Hypothetical Protein 
(Cytochrome P450) 
4e-119 Hypothetical Protein 
(Cytochrome P450) 
Ctg699_Orf00001 3302-4440 6e-140 Hypothetical Protein (Short 
Chain Dehydrogenase; 
Provisional) 
5e-35 Hypothetical Protein (ARM) 
Ctg699_Orf0002 5084-5792 2e-143 Hypothetical Protein (Cupin 2) 2e-37 Hypothetical Protein (Predicted 
Acyl Esterases) 
Ctg699_Orf003 6296-7285 5e-164 Hypothetical Protein (Fabg - 3-
Ketoacyl-(Acyl-Carrier-Protein) 
Reductase) 
6e-27 Hypothetical Protein  (OYE Like 
FMN) 
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Ctg699_Orf04 8929-17316 0 Polyketide Synthase-Like 
Protein (Β-Ketoacyl Synthase) 
2e-148 Hypothetical Protein (Acyl 
Transferase Domain In 
Polyketide Synthase) 
Ctg699_Orf5 30824-31471 2.4 Hypothetical Protein (RNA-
Binding Protein Of The Puf 
Family, Translational Repressor) 
0.042 Hypothetical Protein (Pumilio-
Family RNA Binding Domain) 
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Ctg761_Orf000000 247-1023 3e-14 Hypothetical Protein 
(Mitochondrial Carrier Protein) 
6e-08 Hypothetical Protein 
(Mitochondrial Carrier Protein) 
Ctg761_Orf00001 3383-5452 4e-13 Hypothetical Protein (Caic - 
Acyl-Coa Synthetases (AMP-
Forming)) 
1e-15 Hypothetical Protein (Caic - 
Acyl-Coa Synthetases (AMP-
Forming)) 
Ctg761_Orf0002 6098-9032 9e-154 Hypothetical Protein (Amino 
Acid Kinase Family) 
4e-180 Hypothetical Protein (Amino Acid 
Kinase Family) 
Ctg761_Orf003 9869-17713 6e-85 Hypothetical Protein 
(Acetyltransferase Domain) 
9e-128 Hypothetical Protein (Acyl 
Transferase Domain In 
Polyketide Synthase Enzymes) 
Ctg761_Orf04 17874-18613 9e-44 Hypothetical Protein (Β-Ketoacyl 
Synthase) 
4e-51 Hypothetical Protein (Acyl 
Transferase Domain In 
Polyketide Synthase Enzymes) 
Ctg761_Orf5 20080-20796 4e-12 Hypothetical Protein (Mhpc - 
Predicted Hydrolases Or 
Acyltransferases) 
3e-04 Hypothetical Protein (Polyketide 
Synthase Modules And Related 
Proteins) 
Ctg761_Orf6 21406-23296 4e-133 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
2e-13 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
Ctg761_Orf7 24985-28770         
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Ctg789_Orf13   0 Hypothetical Protein (PHD-
Finger) 
2e-21 Hypothetical Protein (PHD-
Finger) 
Ctg789_Orf14 50669-52225 0 Hypothetical Protein (PA2G4-
Like) 
0 Hypothetical Protein (PA2G4-
Like) 
Ctg789_Orf15 53823-56063 0 Hypothetical Protein (SNF5) 2e-172 Hypothetical Protein (SNF5) 
Ctg789_Orf16 57366-61955 3e-87 Hypothetical Protein 5e-32 Hypothetical Protein (TFIIF 
Alpha) 
Ctg789_Orf17 64196-65621 1e-156 Hypothetical Protein (Herpes 
BLLF1) 
1.4 Hypothetical Protein (STAG 
Domain) 
Ctg789_Orf18 66237-67551         
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Ctg868_Orf000000 1174-4675 0 Hypothetical Protein (AFD Class 2e-44 Hypothetical Protein (AMP-
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I) Binding Enzyme) 
Ctg868_Orf00001 8133-9623 4e-116 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
1.1 Hypothetical Protein (PX 
SNARE) 
Ctg868_Orf0002 11793-12482 3e-25 Hypothetical Protein (MDR7 - 
Medium Chain 
Dehydrogenase/Reductase) 
2e-25 Zinc-Containing Alcohol 
Dehydrogenase, Putative 
(MDR7 - Medium Chain 
Dehydrogenase/Reductase) 
Ctg868_Orf003 17121-18004 1e-122 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
4e-38 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
Ctg868_Orf04 18442-19760 0 Hypothetical Protein 1.9 Hypothetical Protein (FDH GDH 
Like) 
Ctg868_Orf5 20852-21557 5e-60 Putative Aspartate 
Aminotransferase 
(Aminotransferase Class I And 
II) 
7e-67 Hypothetical Protein 
(Aminotransferase Class I And 
II) 
Ctg868_Orf6 22779-23226         
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Ctg969_Orf0002 12853-14648 4e-74 Hypothetical Protein (Amidase) 5e-25 Hypothetical Protein (Amidase) 
Ctg969_Orf003 18781-19623 5e-169 Hypothetical Protein (ICL PEPM) 2e-52 Hypothetical Protein (ICL PEPM) 
Ctg969_Orf04 22003-23781 0 Hypothetical Protein (Peptidase 
S9) 
2e-20 Hypothetical Protein (Peptidase 
S9) 
Ctg969_Orf5 24394-27067 0 Oxidosqualene:Lanosterol 
Cyclase 
0 Oxidosqualene:Lanosterol 
Cyclase 
Ctg969_Orf6 29430-30103 9e-126 Hypothetical Protein (Ank 2) 2e-21 Hypothetical Protein (Ank 2) 
Ctg969_Orf7 30149-31663 1.3 Hypothetical Protein (Ank 2) 0.19 Hypothetical Protein (Oxidase 
Reductase) 
Ctg969_Orf8 33173-34470 8e-146 Hypothetical Protein (FOG:L Zn-
Finger) 
3e-30 Hypothetical Protein (Fungal TF 
MHR) 
Ctg969_Orf9 38510-38518         
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Ctg980_Orf16 46126-49113 0 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
1e-110 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
Ctg980_Orf17 49110-51175 2e-72 Hypothetical Protein (Verru 
Chthon Cassette Protein C) 
9e-65 Putative Transcription Factor 
With C2H2 And Zn(2)-Cys(6) 
DNA Binding Domain 
Ctg980_Orf18 53354-55778 0 Hypothetical Protein (Trp-Synth- 2e-81 Metallopeptidase, Putative (Trp-
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Beta II) Synth-Beta II) 
Ctg980_Orf19 55812-58393 0 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
0 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
Ctg980_Orf20 58977-59437 5e-38 Hypothetical Protein (Dabb - 
Stress Responsive A/B Barrel 
Domain) 
4e-13 Conserved Hypothetical Protein 
(Dabb - Stress Responsive A/B 
Barrel Domain) 
Ctg980_Orf21 60961-62168 0.069 Hypothetical Protein (Predicted 
Zn-Dependent Peptidases, 
Insulinase-Like) 
0.092 Hypothetical Protein (AAA+) 
Ctg980_Orf22 66048-69958 0 Non-Ribosomal Peptide 
Synthetase (Adenylation 
Domain) 
0 Hypothetical Protein 
(Condensation Domain) 
Ctg980_Orf23 70963-72763 0 Cytochrome P450 0 Cytochrome P450, Putative 
Ctg980_Orf24 73394-74831 0 Hypothetical Protein 
(Cytochrome B5-Like 
Heme/Steroid Binding Domain) 
2e-166 Hypothetical Protein 
(Cytochrome B5-Like 
Heme/Steroid Binding Domain) 
Ctg980_Orf25 77197-79117 0 Hypothetical Protein (3-
Hydroxybutyryl-Coa 
Dehydrogenase, Validated) 
0 3-Hydroxybutyryl-Coa 
Dehydrogenase, Validated 
Ctg980_Orf26 79130-79297         
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Ctg1001_Orf10 30521-30916 2e-67 Hypothetical Protein (Ribosomal 
P2) 
2e-25 Hypothetical Protein (Ribosomal 
P2) 
Ctg1001_Orf11 42542-43485 0.001 Hypothetical Protein 7e-73 Hypothetical Protein 
Ctg1001_Orf12 45194-45797 4e-92 Hypothetical Protein (Aldolase II) 1e-25 Hypothetical Protein (Aldolase II) 
Ctg1001_Orf13 46972-48409 6e-72 Acyl-Coa Synthetase (Caic) 2e-19 Hypothetical Protein (AFD Class 
I) 
Ctg1001_Orf14 50486-57860 0 Polyketide Synthase (Acyl 
Transferase Domain) 
0 Hypothetical Protein (Acyl 
Transferase Domain) 
Ctg1001_Orf15 58336-62163         
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Ctg1006_Orf000000 493-735 0.023 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
0.12 Hypothetical Protein (Glyco 32) 
Ctg1006_Orf00001 3916-6711 0 Aminoadipate Reductase 
(Adenylation Domain Of NRPS) 
1e-177 Hypothetical Protein 
(Condensation Domain) 
Ctg1006_Orf0002 7624-8809 2e-109 Hypothetical Protein (Cysteine 2e-37 Hypothetical Protein (Trp-Synth-
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Synthase) Beta II) 
Ctg1006_Orf003 9601-9795      
Ctg1006_Orf04 12907-13404 7e-12 Glutamate-Ammonia Ligase 2e-09 Hypothetical Protein (Glutamine 
Synthetase) 
Ctg1006_Orf5 14753-16283 0 Putative Acyl-Coa 
Dehydrogenase (Caia) 
6e-97 Hypothetival Protein (Acyl-Coa 
Dehydrogenases) 
Ctg1006_Orf6 17532-20822 4e-116 Multidrug Resistance-Associated 
Protein 
4e-12 Hypothetical Protein (CFTR 
Protein) 
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Ctg1072_Orf000000 443-2798 2e-158 Non-Ribosomal Peptide 
Synthetase (Condensation 
Domain) 
1e-52 Hypothetical Protein (Polyketide 
Synthase Modules And Related 
Proteins) 
Ctg1072_Orf00001 4154-5044         
19 
T
e
r
p
e
n
e
 
Ctg1114_Orf000000 4480-8385 9e-173 Serine/Threonine Protein Kinase 9e-13 Hypothetical Protein (Protein 
Kinase, Catalytic Domain) 
Ctg1114_Orf00001 10224-11378 0 Hypothetical Protein (Pex24p) 2e-108 Hypothetical Protein (Pex24p) 
Ctg1114_Orf0002 14765-16757 0 Geranylgeranyl Pyrophosphate 
Synthase (Trans IPPS HT) 
7e-106 Hypothetical Protein 
(Geranylgeranyl Pyrophosphate 
Synthase (Trans IPPS HT)) 
Ctg1114_Orf003 18039-19984 1e-164 Hypothetical Protein (CDC 14) 1e-70 Hypothetical Protein (CDC 14) 
Ctg1114_Orf04 22189-23724 0 Hypothetical Protein (IDO) 3e-151 Hypothetical Protein (IDO) 
Ctg1114_Orf5 25889-26646 0.86 Hypothetical Protein (Pleiotropic 
Drug Resistance) 
5.8 Hypothetical Protein 
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Ctg1191_Orf000000 3129-3666         
Ctg1191_Orf00001 6627-7780 1e-11 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
6e-05 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
Ctg1191_Orf0002 9491-10045 1e-61 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
1e-42 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
Ctg1191_Orf003 12631-13057 2e-15 Hypothetical Protein (Short 
Chain Dehydrogenase, 
Validated) 
2e-14 Putative Sterigmatocystin 
Biosynthesis Ketoreductase 
(Stce) 
Ctg1191_Orf04 18036-21122 9e-93 Hypothetical Protein 
(Adenylation Domain) 
8e-42 Hypothetical Protein 
(Adenylation Domain) 
Ctg1191_Orf5 21778-23373 9e-68 Multidrug Resistance Protein 
(CFTR Protein) 
8e-48 Hypothetical Protein (Multidrug 
Resistance Protein (Mdr1)) 
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Ctg1191_Orf6 28522-29759 0.97 Uncharacterised Protein (Mature 
Chain) 
0.77 Hypotyhetical Protein (Urb2) 
Ctg1191_Orf7 30656-31123 7.2 Hypothetical Protein (Protein 
Kinase Domain) 
4.5 Mitochondrial 3-
Hydroxyisobutyryl-Coa 
Hydrolase, Putative 
Ctg1191_Orf8 33924-35571 9e-29 Hypothetical Protein (7-Keto-8-
Aminopelargonate Synthetase 
And Related Enzymes 
5e-46 Hypothetical Protein (Aspartate 
Aminotransferase (AAT) 
Ctg1191_Orf9 36880-37169 4.2 Cytochrome P450 4.6 Hypothetical Protein (MFS1 
(Major Facilitator Superfamily) 
Ctg1191_Orf10 37399-44629 0 Polyketide Synthase (Acyl 
Transferase Domain) 
0 Polyketide Synthase (Acyl 
Transferase Domain) 
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Ctg1249_Orf000000 55-1427 0 Squalene Synthase (Trans-
Isoprenyl Diphosphate 
Synthases, Head-To-Head) 
3e-171 Farnesyl-Diphosphate 
Farnesyltransferase, Putative 
Ctg1249_Orf00001 3576-4397 4e-175 Hypothetical Protein 
(Nucleoside-Diphosphate-Sugar 
Epimerases) 
2.4 CBF5 EMENI 
Centromere/Microtubule Binding 
Protein CBF5 
Ctg1249_Orf0002 4998-6675 0 Dnaj-Class Molecular 
Chaperone With C-Terminal Zn 
Finger Domain 
8e-163 Dnaj-Class Molecular 
Chaperone With C-Terminal Zn 
Finger Domain 
Ctg1249_Orf003 8127-10565 6e-165 Hypothetical Protein (DNA 
Polymerase III Subunits Gamma 
And Tau; Provisional) 
2e-36 Hypothetical Protein (Large 
Tegument Protein UL36, 
Provisional) 
22 
O
t
h
e
r
 
Ctg1338_Orf000000 1391-2591 0 Hypothetical Protein (Cinnamyl-
Alcohol Dehydrogenase Family 
Protein) 
4e-24 Hypothetical Protein (Cinnamyl-
Alcohol Dehydrogenase Family 
Protein) 
Ctg1338_Orf00001 11690-12264 1.5 Hypothetical Protein 2.8 DNA-Ligase 
Ctg1338_Orf0002 14830-17835 2e-98 Non-Ribosomal Peptide 
Synthetase 
(Phosphopantetheine 
Attachment Site) 
2e-45 Hypothetical Protein 
(Adenylation Domain) 
Ctg1338_Orf003 19609-20789 7e-11 Non-Ribosomal Peptide 
Synthetase (Acyl Transferase 
Domain) 
1e-10 Conserved Hypothetical Protein 
(Adenylation Domain) 
Ctg1338_Orf04 30925-31295 5.1 Hypothetical Protein (Protein 1.2 Hypothetical Protein (IKI3 
80 
 
Kinases) Family) 
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Ctg1445_Orf7 23816-26716 0 Hypothetical Protein (Reca-Like 
Ntpases) 
9e-129 Hypothetical Protein (DEAD-Like 
Helicases Superfamily) 
Ctg1445_Orf8 2949-28631 0 Hypothetical Protein (WD40 
Domain) 
0 Hypothetical Protein (WD40 
Domain) 
Ctg1445_Orf9 34620-34998 4e-53 Hypothetical Protein (S-
Adenosylmethionine-Dependent 
Methyltransferases, Class I) 
9.9 Hypothetical Protein (Rpob - 
DNA-Directed RNA Polymerase) 
Ctg1445_Orf10 35213-35368 7e-10 Hypothetical Protein (A-
Adenosylmethionine-Dependent 
Methyltransferases) 
3.7 Hypothetical Protein (RNA-
Binding Proteins) 
Ctg1445_Orf11 36130-37301 0 Terpene Synthase (Isoprenoid 
Biosynthesis Enzymes, Class I) 
0.032 Hypothetical Protein (Isoprenoid 
Biosynthesis Enzymes, Class I) 
Ctg1445_Orf12 37588-38355 3e-158 Carbohydrate Esterase Family 
Protein 4 
3e-72 Hypothetical Protein (Predicted 
Xylanase/Chitin Deacetylase) 
Ctg1445_Orf13 39112-40403 0 Hypothetical Protein 
(Cystathionine Beta-
Lyases/Cystathionine Gamma-
Synthases) 
5e-151 Cystathionine Gamma-Synthase 
(Cystathionine Beta-
Lyases/Cystathionine Gamma-
Synthases) 
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Ctg1455_Orf00001 8261-9292 0 Hypothetical Protein (NADB 
Rossmann) 
4e-12 Isoflavone Reductase Family 
Protein  
Ctg1455_Orf0002 11028-12148 0 Hypothetical Protein (Cinnamyl-
Alcohol Dehydrogenase Family 
Protein) 
5e-97 Hypothetical Protein (Cinnamyl-
Alcohol Dehydrogenase Family 
Protein) 
Ctg1455_Orf003 13064-14583 0 Hypothetical Protein (5beta-
Reductase-Like Proteins) 
1e-124 Hypothetical Protein (5beta-POR 
Like SDR A) 
Ctg1455_Orf04 19836-21352 0 Hypothetical Protein (NAD(P) +- 
Dependent Aldehyde 
Dehydrogenase Superfamily) 
0 Hypothetical Protein (Aldehyde 
Dehydrogenase Family 2 
Member) 
Ctg1455_Orf5 23583-25214 0 Hypothetical Protein (Choline 
Dehydrogenase And Related 
Flavoproteins) 
0 Hypothetical Protein (Choline 
Dehydrogenase And Related 
Flavoproteins) 
Ctg1455_Orf6 25861-33183 0 Non-Ribosomal Peptide 
Synthetase (Adenylation 
Domain) 
6e-57 Hypothetical Protein 
(Adenylation Forming Domain, 
Class I) 
81 
 
Ctg1455_Orf7 42995-44778 0 Hypothetical Protein (L-Lysine 6-
Monooxygenase) 
9e-144 Hypothetical Protein (L-Lysine 6-
Monooxygenase) 
Ctg1455_Orf8 47972-52330 0 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
6e-89 Hypothetical Protein (Nudix 
Hydrolase 7) 
Ctg1455_Orf9 52358-54104 0 Hypothetical Protein (Two 
Conserved Tryptophans 
Domain) 
6e-129 Hypothetical Protein 
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Ctg1457_Orf000000 1287-2229 0 Hypothetical Protein (NADB 
Rossmann) 
4e-60 Hypothetical Protein (Short 
Chain Dehydrogenase) 
Ctg1457_Orf00001 2935-4492 0 Hypothetical Protein 
(Pyoverdine/Dityrosine 
Biosynthesis Protein) 
2e-61 Hypothetical Protein 
(Pyoverdine/Dityrosine 
Biosynthesis Protein) 
Ctg1457_Orf0002 6628-10438 0 Hypothetical Protein (Caic - 
Acyl-Coa Synthetases (AMP-
Forming)) 
4e-82 Hypothetical Protein (AMP-
Binding Enzyme) 
Ctg1457_Orf003 11009-11962 6e-158 Hypothetical Protein (NADB 
Rossmann) 
3e-93 Hypothetical Protein (3-Ketoacyl-
(Acyl-Carrier-Protein) 
Reductase) 
Ctg1457_Orf04 13525-16203 2e-115 Hypothetical Protein 
(Glutathione S-Transferase 
[Posttranslational Modification, 
Protein Turnover, Chaperones] 
2e-40 Glutathione Transferase, 
Putative 
Ctg1457_Orf5 17976-18353 2e-33 Hypothetical Protein (AAA-Like 
Domain) 
9e-15 Conserved Hypothetical Protein 
Ctg1457_Orf6 22255-23689 0 Conserved Hypothetical Protein 
(2-Polyprenyl-6-Methoxyphenol 
Hydroxylase And Related FAD-
Dependent Oxidoreductases) 
9e-22 Hypothetical Protein (Salicylate 
Hydroxylase) 
Ctg1457_Orf7 24785-25728 0 Hypothetical Protein (Cysg - 
Siroheme Synthase) 
2e-116 Siroheme Synthase Met8, 
Putative 
Ctg1457_Orf8 26323-27815 0 Hypothetical Protein (FYVE 
Domain; Zinc-Binding Domain) 
2e-109 Hypothetical Protein (FYVE 
Domain; Zinc-Binding Domain) 
Ctg1457_Orf9 29341-31757 0 Hypothetical Protein (Kila-N 
Domain) 
3e-157 Hypothetical Protein (Kila-N 
Domain) 
82 
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Ctg1464_Orf000000 537-2701 6e-50 Non-Ribosomal Peptide 
Synthease (NRPS Sidn3 Like 
(Adenylation Domain)) 
3e-48 Non-Ribosomal Peptide 
Synthease (NRPS Sidn3 Like 
(Adenylation Domain)) 
Ctg1464_Orf00001 3338-3961 9e-32 Non-Ribosomal Peptide 
Synthetase 
(Phosphopantetheine 
Attachment Site) 
4e-28 Hypothetical Protein 
(Adenylation Domain) 
Ctg1464_Orf0002 10332-11059 2e-28 Non-Ribosomal Peptide 
Synthetase (Adenylation 
Domain) 
9e-29 Hypothetical Protein 
(Adenylation Domain) 
Ctg1464_Orf003 18662-19797 4e-96 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
0.43 Putative Zn(II)2Cys6 
Transcription Factor (GAL4) 
Ctg1464_Orf04 21563-21633 0.026 Putative Stress Activated 
Mitogen Activated Protein 
Kinase Interacting Protein Sin1 
0.006 Conserved Hypothetical Protein 
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Ctg1540_Orf0002 10893-12821 8e-90 Hypothetical Protein (AAA+) 5e-37 Hypothetical Protein (AAA) 
Ctg1540_Orf003 13294-15194 3e-106 Non-Ribosomal Peptide 
Synthetase (Adenylation 
Domain) 
3e-101 Hypothetical Protein 
(Adenylation Domain) 
Ctg1540_Orf04 20263-20882 2.1 Hypothetical Protein 5.1 Hypothetical Protein 
(Mitochondrial Carrier Protein) 
Ctg1540_Orf5 21085-22146 1.4 Hypothetical Protein (Type 1 
Glutamine Amidotransferase 
(Gatase1)-Like Domain 
0.085 Hypothetical Protein (GAL4 - 
GAL4-Like Zncys6 Binuclear 
Cluster DNA-Binding Domain) 
Ctg1540_Orf6 23323-24735 1e-172 Hypothetical Protein 
(Adenosylmethionine-8-Amino-
7-Oxononanote 
Aminotransferase) 
8e-122 Aminotransferase, Class III 
Ctg1540_Orf7 26046-32361 1e-53 Non-Ribosomal Peptide 
Synthetase (Adenylation 
Forming Domain) 
4e-66 N-(5-Amino-5-
Carboxypentanoyl)-L-Cysteinyl-
D-Valine Synthase 
Ctg1540_Orf8 33167-34614 0 Hypothetical Protein (Nuf2) 1e-130 Nuf2 
Ctg1540_Orf9 38327-40524 0 Hypothetical Protein (Adaptin N) 0 Hypothetical Protein (Adaptin N) 
Ctg1540_Orf10 40905-41136         
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Ctg1556_Orf0002 12866-13542 9e-75 Hypothetical Protein (GGCT- 1e-10 Hypothetical Protein (GGCT-Like 
83 
 
Like Domain) Domain) 
Ctg1556_Orf003 18280-19545 0 Hypothetical Protein (Glyco 
Hydro 61) 
9e-69 Hypothetical Protein (Glyco 
Hydro 61) 
Ctg1556_Orf04 20412-21050 7.1 Hypothetical Protein (NADB 
Rossmann) 
1.8 Hypothetical Protein (Ubih - 2-
Polyprenyl-6-Methoxyphenol 
Hydroxylase And Related FAD-
Dependent Oxidoreductases) 
Ctg1556_Orf5 21483-23846 3e-89 Hypothetical Protein (Protein Of 
Unknown Function) 
6e-14 Hypothetical Protein (Protein Of 
Unknown Function) 
Ctg1556_Orf6 25752-27348 0 Hypothetical Protein (SMI1 
KNR4) 
3e-135 Hypothetical Protein (SMI1 
KNR4) 
Ctg1556_Orf7 31459-31735 0.006 Hypothetical Protein (Metallo-
Beta-Lactamase Superfamily) 
7.0 N-(5-Amino-5-
Carboxypentanoyl)-L-Cysteinyl-
D-Valine Synthase 
Ctg1556_Orf8 33410-41280 0 Polyketide Synthase (Acyl 
Transferase Domain) 
1e-149 Hypothetical Protein (Acyl 
Transferase Domain) 
Ctg1556_Orf9 42384-43810 8e-151 Hypothetical Protein 
(Cytochrome P450) 
2e-52 Hypothetical Protein 
(Cytochrome P450) 
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Ctg1612_Orf000000 400-7768 0 Polyketide Synthase (Acyl 
Transferase Domain) 
3e-124 Hypothetical Protein (Acyl 
Transferase Domain) 
Ctg1612_Orf00001 8496-9407 4e-95 Hypothetical Protein (Znf C3H1) 1e-09 Hypothetical Protein (F0F1 ATP 
Synthase Subunit B) 
 
